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ABSTRACT 
Introduction: Endothelial dysfunction is an early precursor of cardiovascular disease characterized by 
decreased nitric oxide (NO) levels following the development of oxidative stress. Oxidative stress has 
been shown to result not only in the inactivation of NO itself, but also of endothelial NO synthase (eNOS), 
the enzyme responsible for NO synthesis. This contributes to creating a pro-inflammatory environment in 
the vasculature, which can lead to atherosclerosis and cardiovascular disease. Increased endothelial 
dysfunction and cardiovascular risk have been observed in both HIV-1 infection and antiretroviral therapy 
(ART). 
Objectives: To establish a simulated model of in vitro HIV-1-infection and determine the effects of 
non/nucleoside reverse transcriptase inhibitors (NRTI/NNRTIs) and protease inhibitors (PIs) on markers 
of endothelial function and the expression/activation of important vascular signalling proteins within this 
HIV-1-model. 
Methods: A simulated HIV-1-model was established by adding recombinant HIV-1 proteins (100 ng/ml 
each of Nef, Tat and Gp160) to the growth medium of cultured rat aortic endothelial cells (AECs). 
Subsequently, the effects of NRTI/NNRTIs (efavirenz, emtricitabine and tenofovir) and PIs (lopinavir and 
ritonavir) on these HIV-1 exposed AECs were determined using fluorescent probes to assess cell viability, 
NO-production and oxidative stress via reactive nitrogen species (RNS) production. The 
expression/activation of important vascular signalling proteins, including eNOS and IκBα (an inhibitor of 
the inflammatory NFκB signalling pathway), was also evaluated by western blotting.  
Results: Exposure to 100 ng/ml of HIV-1 Nef, Tat and Gp160 for 24 hours led to a significant decrease in 
NO production in AECs (DAF-2/DA fluorescence intensity: 72.05±8.37% vs. 100±1.55%). NRTI/NNRTI 
treatment within an HIV-1-protein medium environment for 24 hours had no effect on NO production, 
possibly abrogating the reduced levels observed with HIV-1-protein treatment on its own. Furthermore, a 
decrease in RNS was observed (DHR-123 fluorescence intensity: 83.19±3.5% vs. 100±0.22%). PI 
treatment within an HIV-1-protein medium environment for 24 hours resulted in a reduction in NO 
production in a concentration-dependent manner (DAF-2/DA fluorescence intensity: 92.74±1.4% vs. 
100±0.67% and 85±1.81% vs. 100±0.56%), probably due to decreased eNOS expression (0.28±0.04 vs. 
1±0.21). Interestingly, neither HIV-1 protein exposure on its own, nor PI treatment in isolation had any 
effects on eNOS. The same was observed for IκBα, where combined HIV-1-protein and PI exposure 
reduced levels (0.37±0.03 vs. 1±0.15) and neither of these treatments in isolation had any effects. 
Conclusion: HIV-1 Nef, Tat and Gp160 attenuated NO production in AECs, while NRTI/NNRTI treatment 
within this HIV-1 protein environment showed minimal adverse effects, and could possibly even be 
beneficial, potentially reversing the detrimental consequences of HIV-1 proteins on NO production. PI 
treatment, on the other hand, seemed to demonstrate a harmful interaction with HIV-1 proteins, resulting 
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in a downregulation of the eNOS-NO biosynthesis pathway. The PI-HIV-1 protein combination was also 
associated with up-regulation of the pro-inflammatory NFκB signalling pathway, which may provide an 
explanation for the decreased eNOS expression.  
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OPSOMMING 
Inleiding: Endoteeldisfunksie is ‟n voorloper van kardiovaskulêre siektes wat gepaard gaan met verlaagde 
stikstofoksied (NO) vlakke as gevolg van oksidatiewe stres. Studies het getoon dat oksidatiewe stres nie 
net NO inaktiveer nie, maar ook endoteel NO sintase (eNOS), die ensiem verantwoordelik vir NO sintese. 
Hierdie dra by tot die ontwikkeling van ‟n pro-inflammatoriese toestand in die vaskulêre omgewing, wat 
kan lei tot aterosklerose en kardiovaskulêre siektes. Verhoogde endoteeldisfunksie en kardiovaskulêre 
risiko is al in beide HIV-1-infeksie en antiretrovirale terapie gemerk. 
Doelstellings: Om ‟n gesimuleerde model van in vitro HIV-1-infeksie te ontwikkel en vas te stel wat die 
gevolge van behandeling met  nie-/nukleosied tru-transkriptase inhibeerders (NRTI/NNRTIs) en protease 
inhibeerders (PIs) op merkers van endoteeldisfunksie en die uitdrukking/aktivering van belangrike 
vaskulêre seinproteïne in hierdie HIV-1-model is. 
Metodes: ‟n Gesimuleerde HIV-1-model is ontwikkel deur rekombinante HIV-1 proteïne (100 ng/ml elk van 
Nef, Tat en Gp160) by die groei media van gekweekte rot aorta endoteelselle (AESe) te voeg. Hierna is 
die uitwerking van NRTI/NNRTIs (efavirenz, emtricitabine en tenofovir) en PIs (lopinavir en ritonavir) op 
die HIV-1 blootgestelde AESe vasgestel met die gebruik van fluoressensie ondersoeke om sel 
lewensvatbaarheid, NO-produksie en oksidatiewe stres via die produksie van reaktiewe stikstof spesies 
(RSS) te assesseer. Die uitdrukking/aktivering van belangrike vaskulêre seinproteïne, insluitend eNOS en 
IκBα (‟n onderdrukker van die inflammatoriese NFκB seinpaaie), is geëvalueer deur middel van western 
blot analises.  
Resultate: Blootstelling aan 100 ng/ml elk van HIV-1 Nef, Tat en Gp160 vir 24 uur het gelei tot ‟n 
beduidende vermindering in NO produksie in AESe (DAF-2/DA fluoressensie intensiteit: 72.05±8.37% vs. 
100±1.55%). NRTI/NNRTI behandeling in ‟n HIV-1-protein medium omgewing vir 24 uur het geen 
uitwerking op NO produksie gehad nie en het moontlik die verminderde vlakke weens HIV-1-protein 
behandeling op sy eie verbeter. Bowendien, is ‟n afname in RSS gemerk (DHR-123 fluoressensie 
intensiteit: 83.19±3.5% vs. 100±0.22%). PI behandeling in ‟n HIV-1-protein media omgewing vir 24 uur 
het verminderde NO produksie tot gevolg gehad in ‟n dosis-afhanklike wyse (DAF-2/DA fluoressensie 
intensiteit: 92.74±1.4% vs. 100±0.67% en 85±1.81% vs. 100±0.56%), waarskynlik as gevolg van 
verminderde eNOS uitdrukking (0.28±0.04 vs. 1±0.21). Interessant genoeg, het nóg HIV-1 proteïne, nóg 
PI behandeling op hul eie enige uitwerking op eNOS gehad nie. Dieselfde is waargeneem vir IκBα, waar 
blootstelling aan gekombineerde HIV-1-protein en PI behandeling IκBα vlakke verlaag het (0.37±0.03 vs. 
1±0.15), terwyl die HIV-1 en PI behandelings op hul eie geen uitwerking gehad het nie. 
Gevolgtrekking: HIV-1 Nef, Tat en Gp160 het NO produksie in AESe verminder, terwyl NRTI/NNRTI 
behandeling binne hierdie HIV-1 proteïen omgewing minimale negatiewe gevolge getoon het en moontlik 
selfs voordelig was, deur potensieel die negatiewe uitwerkings van  HIV-1 proteïne op NO produksie te 
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herstel. PI behandeling, aan die ander kant, het geblyk om ‟n skadelike interaksie met die HIV-1 proteïne 
te toon, wat gelei het tot ‟n afname in eNOS-NO biosintese. Die PI-HIV-1 proteïen kombinasie was ook 
geassosieer met ‟n opregulering van die pro-inflammatoriese  NFκB seinpaaie, wat moontlik ‟n verklaring 
is vir die verminderde eNOS uitdrukking.  
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CHAPTER 1: LITERATURE REVIEW 
 
1.1. CARDIOVASCULAR DISEASE (CVD) 
1.1.1 Epidemiology 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. In 2015, an estimated 17.7 
million deaths were attributed to CVD, which represented 31% of the global total, and of these deaths, 
more than 70% occurred in low- and middle-income countries (WHO, 2017). The bulk of cardiovascular 
deaths are attributed to two conditions, namely, ischaemic heart disease and cerebrovascular disease 
(predominantly ischaemic stroke). Globally, these are the number one and two causes of years of life lost, 
respectively (Wang et al., 2016). Underpinning both these conditions is a chronic inflammatory state of 
the arteries: atherosclerosis (Nabel and Braunwald, 2012; Barquera et al., 2015).   
1.1.2 Atherosclerosis 
Atherosclerosis occurs at vulnerable sites in large and medium sized arteries, where it results in the 
development of atherosclerotic plaques. It is a chronic inflammatory process which develops in response 
to the biologic effects of cardiovascular risk factors. Joseph et al. (2017) showed that short-term changes 
in arterial inflammation could predict long-term atherosclerosis progression. Participants with increased 
carotid inflammation over a six-month period, showed MRI evidence of increased carotid mean wall 
thickness and mean wall area at two years. Conversely, in participants without increased arterial 
inflammation, no significant long-term atherosclerosis progression was observed. Exposure to 
cardiovascular risk factors activates the vascular endothelial cells, resulting in changes in their 
permeability, which promotes the entry of low-density lipoprotein (LDL) particles into the sub-endothelial 
space of the intima layer of the blood vessel. Once in the intima, these LDL particles are modified, which 
includes being oxidised by reactive oxygen species (ROS), and this perpetuates the activation process. 
Consequently, these endothelial cells release chemokines into the bloodstream which attract circulating 
leukocytes, especially monocytes. These monocytes then adhere to the activated endothelium and enter 
the sub-endothelial space, where they differentiate into macrophages which ingest the various LDL 
particles and eventually transform into lipid filled foam cells (Figure 1.1) (Mestas and Ley, 2008; Insull, 
2009; Moore and Tabas, 2011; Nabel and Braunwald, 2012), a process in which oxidative stress plays a 
crucial role (Förstermann, Xia and Li, 2017).  
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Figure 1.1: Foam cell formation. Adapted from Nabel and Braunwald (2012). 
 
Elevated levels of LDL cholesterol in the blood plasma aggravates the atherosclerotic process, since, in 
this scenario, levels of LDL-influx into the sub-endothelial space exceeds the eliminating capacity. Arterial 
wall LDL accumulation is either the result of increased lipoprotein influx caused by enhanced endothelial 
permeability and subsequent LDL deposition or a decreased lipoprotein efflux. At areas of disturbed flow 
in the vasculature, LDL influx from the circulation is even higher due to flow stagnation and longer contact 
between the blood and vascular endothelial cells. Should serum LDL-levels remain high, a self-
perpetuating process develops, where the accumulation of excess extracellular LDL triggers a continuous 
inflammatory recruitment of monocytes and the subsequent build-up of macrophage foam cells (Figure 
1.2) (Moore and Tabas, 2011; Förstermann, Xia and Li, 2017). Oxidised LDL particles cause endoplasmic 
reticulum (ER) stress within the macrophages and should this stress continue, it can lead to macrophage 
apoptosis (Sanson et al., 2009). Initially, these apoptotic macrophage foam cells can be removed by 
phagocytes, but if the process is perpetuated and the lesion progresses, the clearance of apoptotic foam 
cells becomes ineffective and a necrotic core develops within the atherosclerotic plaque (Moore and 
Tabas, 2011). Under the vascular endothelium, fibrous tissue then accumulates to form a cap over this 
lipid-rich necrotic core (Insull, 2009). 
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Figure 1.2: Atherosclerotic plaque formation. Adapted from Nabel and Braunwald (2012). 
 
1.1.3 Traditional Risk Factors 
The underlying causes of atherosclerosis and consequent cardiovascular disease are multiple and 
complex, however, the INTERHEART study (Yusuf et al., 2004), a large case-control study, has identified 
nine potentially modifiable factors that seem to be associated with more than 90% of the risk for an acute 
myocardial infarction: Smoking, abnormal lipids, adverse psychosocial factors, abdominal obesity, 
diabetes, and hypertension were associated with increased myocardial infarction risk, while a daily 
vegetable and fruit intake, physical exercise and the moderate consumption of alcohol were considered 
protective. 
Smoking 
Exposure to cigarette smoke  results in endothelial cell activation, dysfunction, injury and death, leading 
to lipid accumulation and the recruitment of leukocytes (Morris et al., 2015). In people aged 60 years and 
older, smoking strongly correlates with acute coronary events, stroke, and cardiovascular deaths. In this 
cohort, being a smoker advanced the risk of dying from CVD by 5.5 years compared to non-smokers. 
Among smokers, the excess risk also increased with greater cigarette consumption and in former 
smokers the risk decreased with time after quitting in a dose-response manner (Mons et al., 2015). A 
meta-analysis by Hackshaw et al. (2018) found that a major proportion of the risk of coronary heart 
disease and stroke came from smoking only a few cigarettes.  
Abnormal lipids 
LDL cholesterol is a primary causal agent in the development of atherosclerosis and high serum levels 
are an essential determinant of cardiovascular risk. LDL cholesterol reduction with statin therapy has 
consistently been shown to be a safe and highly effective method to reduce cardiovascular risk (Ridker, 
2014). Cholesterol lowering with a low dose of rosuvastatin therapy was associated with a significant 
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reduction in cardiovascular events even in individuals who did not suffer from CVD and who were only at 
intermediate risk (Yusuf et al., 2016). In contrast with LDL cholesterol, high-density lipoprotein (HDL) 
cholesterol protects against atherosclerosis and is inversely associated with coronary heart disease risk. 
HDL cholesterol alleviates endothelial dysfunction, aids in the removal of excess cholesterol from 
macrophages and has antioxidant, anti-inflammatory and antiapoptotic properties. However, under certain 
circumstances, HDL can become dysfunctional and loose its atheroprotective properties (Rader and 
Hovingh, 2014; Rosenson et al., 2016). Triglycerides, or more specifically triglyceride-rich lipoproteins, 
are considered another causal risk factor for CVD. However, triglycerides can be degraded by most cells, 
whereas cholesterol cannot and thus it is more likely that it is the cholesterol content of these triglyceride-
rich lipoproteins that plays this causal part in CVD development. Plasma triglyceride levels can therefore 
more accurately be described as a marker of remnant cholesterol, which is the cholesterol content of 
triglyceride-rich lipoproteins (Nordestgaard and Varbo, 2014). 
Abdominal obesity 
An association between body weight and CVD has long been established. In the 1980s, The Framingham 
study demonstrated that degree of obesity was an important long-term predictor of CVD incidence, 
particularly in younger participants (Hubert HB, Feinleib M, McNamara PM, 1983). Overweight and 
obesity are risk factors for a number of conditions, including type II diabetes, cancer and CVD (Guh et al., 
2009). In a large longitudinal community- and population-based cohort, greater accumulation of 
abdominal fat volume, including abdominal subcutaneous adipose tissue and visceral adipose tissue, was 
associated with an increased incidence of CVD and adverse changes in cardiovascular risk factors above 
and beyond the risk associated with general- and central adiposity (Lee et al., 2016). 
Diabetes mellitus 
Hyperglycaemia negatively impacts the vasculature in several ways. High glucose concentrations can 
activate nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) in endothelial cells, 
monocyte-derived macrophages and vascular smooth muscle cells which affects the transcription of 
multiple genes. Advanced glycation end-products (AGEs) are formed when proteins and lipids are 
exposed to high concentrations of glucose and this can increase reactive oxygen species (ROS) 
production. In this way high glucose levels lead to oxidative stress. High glucose concentrations can also 
contribute to the modification of lipoproteins which likely promotes atherosclerosis. These lipoprotein 
changes result in reduced cholesterol efflux from macrophages and promote proinflammatory 
phenotypes. Altered lipoprotein particles also activate endothelial cells, increasing adhesion molecule 
expression and the consequent inflammatory response (Mazzone, Chait and Plutzky, 2008). 
Hypertension 
The link between CVD and hypertension is well established. In a meta-analysis by Ettehad et al. (2016), 
blood pressure lowering medication significantly reduced the risk of CVD and CVD mortality in multiple 
populations of patients. A 10 mm Hg reduction in systolic blood pressure decreased the risk of major CVD 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
events by 20%, coronary heart disease by 17%, stroke by 27%, heart failure by 28%, and all-cause 
mortality by 13%.  
Diet 
The link between diet and CVD has lately become a contentious topic. Traditionally, low-fat diets were 
prescribed for reducing weight and cardiovascular risk, however, recently this view has been disputed. 
Both low-fat and low-carbohydrate diets have been shown to be effective for weight-loss yet, low-
carbohydrate diets seem to offer more favourable changes in terms of cardiovascular risk reduction 
(Foster et al., 2010; Bazzano et al., 2014). However, De Souza et al. (2015) found no clear association 
between a higher intake of saturated fats and all-cause mortality, coronary heart disease (CHD), CHD 
mortality, ischemic stroke or type II diabetes in healthy adults. Conversely, the consumption of trans-
unsaturated fatty acids was associated with a 34% increase in all-cause mortality, a 28% increase in the 
risk of CHD mortality and an increased risk of 21% for CHD.  
Physical exercise 
Physical activity has been described as one of the most fundamental factors necessary for maintaining 
health and dispelling cardiovascular risk (Schuler, Adams and Goto, 2013). In 7744 men initially free of 
CVD, being physically active was associated with a reduction in the risk of CVD death, while sedentary 
activities including time spent riding in a car and watching television were predictors of CVD mortality. 
Interestingly, high levels of physical activity were related to reduced CVD mortality even in individuals 
who also spent large amounts of time participating in sedentary activities (Warren et al., 2010). 
1.1.4 Emerging Cardiovascular Risk Factors: HIV and Antiretroviral Therapy 
Since the advent of antiretroviral therapy (ART), human immunodeficiency virus (HIV) has increasingly 
become regarded as a chronic and manageable disease and subsequently new challenges have arisen. 
Comorbidities with non-communicable conditions such as CVD pose additional obstacles for persons 
infected with this virus. Moreover, increased cardiovascular risk has been associated with HIV-infection 
itself as well as with ART. A meta-analysis by Islam et al. (2012) showed that the relative risk of 
developing CVD in HIV-positive persons was 61% higher than that of their HIV-negative counterparts. 
Additionally, the investigators found the cardiovascular risk in people living with HIV receiving highly 
active antiretroviral therapy (HAART) to be double that of treatment-naïve HIV-positive individuals. These 
findings are also echoed by a recent systematic review, meta-analysis and burden assessment, which 
showed the risk of CVD in people living with HIV to be twice that of the uninfected population. 
Furthermore, the authors of this paper purport that the incidence of CVD associated with HIV is 
comparable to that of other high cardiovascular risk groups, including diabetes mellitus. Worryingly, they 
also found sub-Saharan Africa to carry a large proportion of this burden (Shah et al., 2018). Hsue and 
Waters (2018) argue that the time has come to regard HIV infection as a major cardiovascular risk factor, 
together with conditions such as diabetes mellitus, hypertension and hyperlipidaemia. The novel 
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cardiovascular risk factors of HIV and ART will thus be the focus of this thesis, with more detail to follow 
later in the text. 
1.1.5 Progression 
As described above, atherosclerosis begins with the pathophysiological activation of endothelial cells, 
leading to permeability changes and the entry of monocytes and cholesterol containing LDL particles into 
the artery intima. What follows is the development of the atherosclerotic plaque. These plaques are 
responsible for the clinical symptoms associated with CVD. Plaques in the arteries of the heart can cause 
flow-limiting stenosis and this results in stable angina, or they can provoke the formation of a thrombus 
that interrupts blood flow either temporarily, resulting in unstable angina, or a permanently, causing a 
myocardial infarction. The rupture of atherosclerotic plaques exposes procoagulant material within the 
core of the plaque which can initiate the coagulation cascade, prompting thrombosis and also potentially 
resulting in a myocardial infarction (Figure 1.3) (Nabel and Braunwald, 2012). While the process of 
atherogenesis is irreversible, its precursors, endothelial activation and dysfunction fortunately are not. In 
this regard, endothelial dysfunction is thought to be an early predictor of atherosclerosis and subsequent 
CVD (Mudau et al., 2012).  
 
Figure 1.3: Thrombus formation. Adapted from Nabel and Braunwald (2012). 
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1.2. ENDOTHELIAL DYSFUNCTION  
1.2.1 The Vascular Endothelium 
The vascular endothelium, a monolayer of selectively permeable endothelial cells, plays an essential role 
in regulating vascular homeostasis. It responds to various physical and chemical signals by producing a 
broad spectrum of factors that regulate vascular tone, cell adhesion, coagulation, smooth muscle cell 
proliferation and inflammation (Deanfield, Halcox and Rabelink, 2007). One of the vascular endothelium‟s 
primary functions is to maintain the balance between vasodilation and vasoconstriction and nitric oxide 
(NO), a gaseous free radical synthesized by the enzyme endothelial NO synthase (eNOS), is a crucial 
agent in this regard (Davignon and Ganz, 2004; Mudau et al., 2012). 
Endothelial Nitric Oxide Synthase (eNOS) 
In mammals, nitric oxide synthase (NOS) exists in three different isoforms, namely, neuronal NOS 
(nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS). nNOS is expressed in specific neurons of 
the central and peripheral nervous systems. In the central nervous system it plays a role in synaptic 
plasticity and central blood pressure regulation, while in the peripheral nervous system it is involved in 
atypical neurotransmission and penile erection. iNOS plays a role in inflammation and the immune 
response and its transcription is induced by cytokines. eNOS is primarily expressed in endothelial cells 
(Knowles and Moncada, 1994; Luiking, Engelen and Deutz, 2010; Förstermann and Sessa, 2012). In its 
functional form, eNOS exists as a dimer and is regulated by intracellular calcium (Ca²⁺) levels and 
phosphorylation. Phosphorylation of the serine 1177 residue increases enzyme activity, while the 
threonine 495 residue is a negative regulatory site and its phosphorylation results in decreased enzyme 
activity. NOS converts the amino acid ι-arginine into NO and ι-citrulline, utilising oxygen and reduced 
nicotinamide-adenine-dinucleotide phosphate (NADPH) as co-substrates (Figure 1.4) (Davignon and 
Ganz, 2004; Förstermann and Sessa, 2012). 
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Figure 1.4: NO synthesis in an endothelial cell. eNOS activity is regulated by intracellular Ca²⁺ and 
phosphorylation. Protein kinase A (PKA), Protein kinase B (PKB/Akt), AMP-activated kinase (AMPK) and 
calmodulin-dependent kinase II (CaMKII) can all phosphorylate eNOS at Ser1177, thus enhancing the 
enzyme‟s activity. eNOS converts oxygen and ι-arginine into nitric oxide and ι-citrulline. NO decreases 
leukocyte adhesion and in platelets it decreases activation, adhesion and aggregation. It results in the 
relaxation of vascular smooth muscle and reacts with the haemoglobin in red blood cells, increasing 
oxygen delivery to tissues. Figure designed by the author of this thesis, based on content from 
Förstermann and Sessa, (2012) and Gimbrone and García-Cardeña (2016).  
 
Nitric Oxide (NO) 
NO is a powerful vasodilator and functions to maintain the vascular wall in a homeostatic state by 
inhibiting inflammation, cellular proliferation and thrombosis (Deanfield, Halcox and Rabelink, 2007). This 
molecule also protects against atherosclerosis (Förstermann and Sessa, 2012). Its actions were once 
thought to be the doing of a mystery substance termed endothelium-derived relaxing factor (EDRF) until it 
was discovered that NO and EDRF were in fact one and the very same (Palmer, Ferrige and Moncada, 
1987). NO is constitutively synthesized in endothelial cells by eNOS in response to various stimuli. The 
NO then diffuses to adjacent vascular smooth muscle cells where it initiates cell signalling cascades 
resulting in vasorelaxation (Figure 1.5) (Förstermann and Sessa, 2012).  
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Figure 1.5: NO signalling in a vascular smooth muscle cell. NO leads to the downstream 
phosphorylation of protein kinase G (PKG). PKG then causes L-type calcium channels in the muscle cell 
to close, preventing the influx of calcium ions. This inhibits muscle cell contraction and results in 
vasorelaxation. Figure designed by the author of this thesis, based on content from Maron and Michel 
(2012) and Mudau et al. (2012). 
 
1.2.2 Endothelial Dysfunction 
When the vascular endothelium can no longer maintain homeostasis, endothelial dysfunction ensues. 
This pathophysiological state is characterised by a loss of the balance between vasodilation and 
vasoconstriction, with vasoconstriction becoming dominant, and, as mentioned before, it is regarded as 
an early precursor to the development of atherosclerosis and subsequent CVD. Central to endothelial 
dysfunction is reduced NO bioavailability, which can be accounted for by a number of mechanisms 
including reduced eNOS protein levels, decreased substrate and cofactor availability, changes in eNOS 
phosphorylation and furthermore, ROS can inactivate eNOS and scavenge NO itself. Oxidative stress is 
believed to be the putative pathophysiological process responsible for reduced NO bioavailability as it 
results in the modification of both NO and eNOS (Davignon and Ganz, 2004; Liu and Huang, 2008; 
Mudau et al., 2012). 
Oxidative Stress 
When reactive oxygen species (ROS) such as the superoxide anion (O₂¯), hydrogen peroxide (H₂O₂) or 
hydroxyl radical (HO·) overcome cellular antioxidant defences, it results in oxidative stress and whilst NO 
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protects against atherosclerosis, vascular oxidative stress is pro-atherogenic (Förstermann, Xia and Li, 
2017). ROS are generated endogenously, for example via mitochondrial oxidative phosphorylation, 
and/or originate from exogenous sources. Under physiological conditions cells are well equipped to deal 
with ROS (Table 1.1), however, when levels rise beyond the neutralisation capabilities of the cell or when 
there is a decrease in cellular antioxidant capacity, oxidative stress occurs (Ray, Huang and Tsuji, 2012). 
In the context of endothelial dysfunction, oxidative stress has two primary consequences. Firstly, it is 
responsible for the inactivation of NO itself by its reaction with O₂¯, turning it into peroxynitrite (ONOO¯), 
a potent reactive nitrogen species (RNS) (Förstermann and Sessa, 2012; Mudau et al., 2012). This can 
lead to nitrosative stress, a damaging state, detectible via the nitration of the amino acid tyrosine, 
resulting in nitrotyrosine formation (Duncan, 2003). Secondly, oxidative stress can result in the uncoupling 
of eNOS, converting it from a dimer to a monomer that acts as a O₂¯ generating enzyme further 
exacerbating the level of oxidative stress (Förstermann and Sessa, 2012; Mudau et al., 2012). A number 
of factors can contribute to the cellular antioxidant defences being overwhelmed and the development of 
oxidative stress, including irregular blood flow and cardiovascular risk factors (Li, Horke and Förstermann, 
2013; Hsieh et al., 2014). 
Table 1.1: Summary of reactive oxygen species (ROS) producing systems in the vascular wall and 
antioxidant defences. Content from Förstermann, Xia and Li (2017).  
ROS-producing systems Antioxidant enzymes 
NADPH Oxidases 
Two membrane-bound 
subunits: p22phox and a 
Nox homologue. 
Superoxide 
Dismutase 
Catalyzes the dismutation of 
superoxide into oxygen and 
hydrogen peroxide. 
Several cytosolic regulatory 
subunits. 
Produces superoxide. 
Xanthine Oxidase 
Produces superoxide and 
hydrogen peroxide 
Catalase 
Located in peroxisomes 
Catalyses the reduction of 
hydrogen peroxide to oxygen 
and water. 
Mitochondria 
Produce excess ROS under 
pathological conditions, 
including superoxide. 
Glutathione 
Peroxidases 
The major antioxidant enzyme 
within many cells 
Reduces hydrogen peroxide to 
water 
Reduces lipid hydroperoxides 
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Uncoupled eNOS Produces superoxide Paraoxonases 
Family of three proteins 
Reduce oxidative stress 
Decreases lipid peroxidation. 
 
 
Blood Flow 
Endothelial shear stress (ESS) is the parallel frictional drag force acting along the vascular endothelium 
due to blood flow and it plays an integral part in the development of atherosclerosis – especially with 
regards to where atherosclerotic plaques tend to develop. Atherosclerotic plaques do not develop 
randomly, but rather, at susceptible sites in arteries where blood flow is irregular and characterised by low 
and oscillatory endothelial shear stress (ESS) (Cunningham and Gotlieb, 2005; Hsieh et al., 2014). Low 
and oscillatory ESS occur at curved, branched and diverged regions in arteries. Where arteries are 
straight, and the blood flow is laminar, ESS tends to be moderate or physiological. This is termed regular 
flow and atherosclerotic plaques generally do not develop in regions characterised by regular flow 
(Wentzel et al., 2012; Hsieh et al., 2014). 
Regular flow and the resultant moderate or physiological ESS leads to the activation of protein kinase A 
(PKA) which in turn phosphorylates eNOS at Ser1177, increasing the enzyme‟s sensitivity to intracellular 
Ca²⁺, resulting in the synthesis of NO and subsequent vasodilation (Figure 1.4) (Förstermann and Sessa, 
2012). Furthermore, besides the immediate vasodilatory effect, moderate or physiological ESS also 
facilitates more long-term changes through vascular remodelling. Regular flow stimulates NO production 
and attenuates ROS production leading to the generation of an anti-oxidant state and the activation of 
transcription factors that promote an anti-atherogenic vascular wall environment. Contrary to this, irregular 
flow reduces NO production and promotes ROS formation which leads to a state of oxidative stress and 
the activation of inflammatory transcription factors such as NFκB (Hsieh et al., 2014). Multiple pathways 
can lead to the activation of NFκB. The canonical NFκB activation pathway results in the proteolysis of 
IκBα (an inhibitory protein that prevents the translocation of NFκB to the nucleus) and the phosphorylation 
of the RelA/p65 subunit of NFκB on serine 276 (Brasier, 2010). NFκB  and other inflammatory 
transcription factors favour the creation of a pro-atherogenic environment  resulting in the proliferation of 
vascular endothelial and smooth muscle cells, as well as increased leukocyte adhesion (Qi et al., 2011; 
Liao, 2013).  
As multiple cardiovascular risk factors have been implicated in the development of oxidative stress, the 
consequences for these already susceptible sites are cumulative. Hypertension, hypercholesterolemia, 
diabetes mellitus and smoking all induce oxidative stress in the vascular wall with a subsequent decrease 
in NO bioavailability and ensuing endothelial dysfunction (Li, Horke and Förstermann, 2013). Additionally, 
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NO normally has an inhibitory effect on NFκB, however, decreased NO bioavailability caused by 
exposure to cardiovascular risk factors, further enhances the activation of NFκB in areas of irregular flow 
(Liao, 2013).  
Cardiovascular Risk Factors 
Multiple cardiovascular risk factors have been implicated in the development of oxidative stress and 
endothelial dysfunction (Mudau et al., 2012). Risk factors stimulate the production of ROS via multiple 
sources including NADPH oxidases, xanthine oxidase, mitochondria and uncoupled eNOS, consequently 
decreasing NO bioavailability (Förstermann, Xia and Li, 2017). This leads to endothelial dysfunction and 
endothelial cell activation with subsequent atherosclerosis (Mudau et al., 2012). Both native LDL 
cholesterol and minimally oxidised LDL cholesterol have been linked to vascular endothelial 
O₂¯generation (Stepp et al., 2002). In mice and human subjects, fat accumulation was shown to correlate 
with systemic oxidative stress. In the adipose tissue of obese mice ROS production was augmented and 
the expression of antioxidant enzymes decreased. Elevated levels of fatty acids in cultured adipocytes 
increased oxidative stress and this was linked to the dysregulation of adipocytokines (Furukawa et al., 
2004). Hypertension has also been linked to oxidative stress (Montezano et al., 2015) as well as type II 
diabetes. The “Coronary Artery Risk Development In young Adults” (CARDIA) study showed that 
biomarkers of oxidative stress positively correlated with type II diabetes. Additionally higher levels of E-
selectin, a cell-surface adhesion molecule and plasma biomarker of endothelial dysfunction activated by 
proinflammatory cytokines like TNF-α and IL-6 (Liao, 2013), was also strongly associated with type II 
diabetes (Odegaard et al., 2016). The isolated aortic rings of cigarette smoke-exposed mice showed in a 
significant impairment of endothelium-dependent vasorelaxation, indicative of endothelial dysfunction 
(Talukder et al., 2011). Furthermore, both HIV and ART have been linked to oxidative stress and 
endothelial dysfunction (Lambert et al., 2016).  
 
1.3. HUMAN IMMUNODEFICIENCY VIRUS (HIV)  
1.3.1 Epidemiology 
Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) belong to a group of pathogens 
termed lentiviruses, which can infect various mammalian species. The prefix, “lenti” is derived from the 
Latin word, lento, meaning “slow,” as most diseases associated with this group of viruses have a slow 
onset and result in chronic infections (Campbell and Robinson, 1998). Genetically, HIV-1 and HIV-2 are 
only distantly related, but clinically they cause similar symptoms. HIV-2 is largely restricted to West Africa 
and its prevalence is declining. It is not very aggressive and most infected individuals do not progress to 
Acquired Immunodeficiency Syndrome (AIDS) (Sharp and Hahn, 2011), the end-stage disease of HIV-
infection, a consequence of the activation and eventual destruction of the host immune system (Weiss, 
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1993). HIV-1 is responsible for the global pandemic. It is not a single virus, but four distinct lineages: 
groups M, N, O and P, of which group M is the most virulent. Both HIV-1 and HIV-2 evolved following 
zoonotic transfers of lentiviruses infecting primates in West Central Africa, possibly a consequence of 
bushmeat hunting. Four independent cross-species transmission events of Simian Immunodeficiency 
Viruses (SIVs) are believed to be responsible for the human infection by the SIV precursors of each of the 
four HIV-1 lineage groups. Subsequent viral adaptations, aided by the fact that Immunodeficiency Viruses 
evolve rapidly, had to occur to enable these precursors to replicate in their new species host. Of the four 
groups, M was most successful, making it unsurprising that it is this group that drives the global HIV 
pandemic (Sharp and Hahn, 2011). Furthermore, HIV-1 group M consists of a number of subtypes, 
varying in occurrence from region to region across the globe, with the greatest diversity found in Central 
Africa (Hemelaar et al., 2011). In Southern Africa subtype C dominates (Sharp and Hahn, 2011). 
Additionally, since HIV-1 is such a variable pathogen, subtypes do not exist homogenously within infected 
individuals, but as clusters of closely related, yet non-identical viral genomes (McCutchan, 2006). 
In 2015 17.0 million people were living with HIV and receiving antiretroviral therapy worldwide. In 2010 
1.5 million AIDS related deaths were recorded, a figure that decreased to 1.1 million in 2015 (UNAIDS, 
2016). While HIV prevalence is dropping globally, declines are only evident where prevention strategies 
have been broadly implemented and embraced by the target population. Despite intervention, Sub-
Saharan Africa remains the epicentre for the HIV pandemic (Vermund, 2014). A global decline noted in 
annual new infections among adults has, however, plateaued in recent years and, in 2015, remained 
nearly static at about 1.9 million. Notwithstanding, this figure encompasses many disparities, with some 
populations still at a disadvantage (UNAIDS, 2016).  
Young women aged 15-24 years are a group exceedingly at risk for HIV infection, globally this group 
accounted for 20% of new HIV infections among adults in 2015. Other populations at increased risk of 
HIV infection include sex workers, people who inject drugs, transgender people, prisoners and men who 
have sex with men (UNAIDS, 2016). Sex workers face an exceedingly large burden of HIV and access to 
prevention as well as treatment lags behind the general population (Shannon et al., 2015). In countries of 
all incomes, HIV epidemics in men who have sex with men are increasing (Beyrer et al., 2012). 
Furthermore, geographic differences in HIV prevalence exist and, in many countries, HIV incidence tends 
to be higher in urban areas (UNAIDS, 2016). 
HIV-1 is an extremely adept pathogen able to successfully commandeer host cellular processes for its 
own ends, whilst simultaneously neutralising anti-viral defences (Sorin and Kalpana, 2006), all of which is 
achieved utilising only fourteen viral proteins (Turner and Summers, 1999).    
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1.3.2 Structure 
The HIV-1 genome contains 9 main genes: gag, pol, env, tat, rev, vpu, vpr, vif and nef.  Gag encodes for 
three structural proteins, which include matrix proteins, capsid proteins and nucleocapsid proteins. Pol 
encodes for three enzymes that are essential for the synthesis of the viral proteins. They include reverse 
transcriptase, which allows the transcription of single-stranded viral RNA into double-stranded provisional 
DNA that can be integrated into the host cell genome by the enzyme integrase. The third viral enzyme, 
protease, cleaves translated viral precursor proteins produced by hijacked host cell machinery into 
mature proteins. Env encodes for the envelope protein Gp160, comprising two proteins, Gp120 and 
Gp41. The remaining viral genes encode for proteins that perform various accessory and regulatory 
functions. Tat and rev encode for the regulatory proteins, transactivator of transcription (Tat) and 
regulator of expression of the virion (Rev), while vpu, vpr, vif and nef encode for the accessory proteins 
viral protein U (Vpu), viral protein R (Vpr), virus infectivity factor (Vif) and negative regulator factor (Nef) 
(Götte, Li and Wainberg, 1999; Turner and Summers, 1999; Kline and Sutliff, 2008; Freed, 2015).  
The virus envelope is comprised of phospholipids originating from the host cell plasma membrane and 
the envelope proteins are embedded in this membrane. The matrix is located between the envelope and 
the capsid, a cone-shaped structure at the centre of the mature virion. The capsid contains viral RNA, 
enzymes and nucleocapsid proteins (Figure 1.6) (Turner and Summers, 1999). The auxiliary viral 
proteins are expressed at various locations during the virus life cycle, depending on their function (Li et 
al., 2005). 
 
Figure 1.6: A representation of the HIV-1 virus. (Marincowitz et al., 2018) 
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1.3.3 Transmission 
HIV-1 transmission can occur via two routes: exposure to the virus at mucosal surfaces and 
percutaneous inoculation. Transmission probability is dependent on various factors, including coital act 
(Table 2). Early- and late-stage infection, higher viral loads, the presence of other sexually transmitted 
infections, especially ulcerating types, and younger age of the infected partner are all factors significantly 
associated with higher rates of transmission (Wawer et al., 2005; Shaw and Hunter, 2012). Antiretroviral 
therapy has been invaluable in halting HIV transmission, as a reduced viral load protects others from 
infection (Vermund, 2014). A review by Weller and Davis-Beaty indicates that consistent heterosexual 
use of condoms results in an 80% reduction in HIV transmission, however, the studies included did not 
report on the correctness of condom use and quality of the condoms (Weller and Davis-Beaty, 2002). 
Male circumcision is another factor that reduces the chances of contracting HIV – for the circumcised 
individual. Furthermore, socioeconomic variables can influence HIV-1 transmission indirectly.  
Globally, heterosexual transmission is responsible for almost 70% of all HIV-1 infections, while men who 
have sex with men, maternal-infant transmission, and injection drug use accounts for most of the 
remaining transmissions (Shaw and Hunter, 2012). High per-act transmission probability, especially 
receptive anal sex, and casual partnerships are factors that put men who have sex with men at a high risk 
of contracting HIV-1 (Beyrer et al., 2012). Wawer et al. (2005) showed the rate of HIV transmission per 
coital act to be highest during early-stage infection, a time when newly infected individuals undergo 
seroconversion and thus do not know their HIV status or receive ART. Although the rate of transmission 
was also found to be high during late-stage infection, the authors mention that during this stage of the 
disease, individuals report less sexual intercourse and have fewer partners and thus its overall 
contribution to the HIV epidemic is unlikely to be extensive. 
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Table 1.2: HIV-1 Transmission Probability. Adapted from Shaw and Hunter (2012). 
HIV INVASION SITE TRANSMISSION MEDIUM 
TRANSMISSION 
PROBABILITY PER 
EXPOSURE EVENT 
Female genital tract Semen; blood 0.05% –  0.5% 
Male genital tract 
Cervicovaginal and rectal 
secretions; blood 
0.03% – 0.14% 
Rectum Semen; blood 0.33% – 5% 
Upper GI tract 
Semen; blood 0.04% 
Maternal blood and genital 
secretions (intrapartum) 
10% – 20% 
Breast milk 10% – 20% 
Placenta Maternal blood (intrauterine) 5% – 10% 
Bloodstream Blood products, sharps 0.67% – 95% 
 
 
1.3.4 Life Cycle and Pathogenesis 
Activated CD4 T-lymphocytes are the preferred targets of HIV-1, although other cells bearing CD4 
surface proteins can also be infected and CD4-independent infection of cells is possible. The virus 
commandeers the target cell and either utilises its machinery for pro-viral functions, or suppresses cellular 
processes to abate their anti-viral functions. After infection by the founder virus, an exponential increase 
in HIV replication occurs. This is followed by host inflammatory- and immune responses until the viral load 
decreases to a set-point. With time, host CD4 T-cells eventually become depleted and this is the hallmark 
of HIV-infection (Sorin and Kalpana, 2006; Maartens, Celum and Lewin, 2014).  
The HIV-1 life cycle can be divided into two phases. The early phase constitutes all events occurring from 
the moment the HIV-1 virus binds to the surface of the host cell up until the point where the viral DNA is 
integrated into the host cell genome. This is the reason the disease can persist in patients even when 
they are receiving antiretroviral therapy: in the absence of virus production, resting memory T-cells remain 
latently infected as the viral genome is integrated into their DNA. The late phase includes all the 
processes that occur after integration up to the release and maturation of new virions (Freed, 2015). 
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Early Phase 
 
Figure 1.7: Early phase of the HIV-1 life cycle (Campbell and Hope, 2015) 
 
Binding and entry: HIV-1 enters the host cell via interactions between the virus envelope glycoprotein, 
Gp160, with CD4 receptors and co-receptor C-C chemokine receptor 5 (CCR5) or C-X-C chemokine 
receptor 4 (CXCR4) on the surface of the host cell. Gp160 is comprised of two associated envelope 
proteins, namely, Gp120 and Gp41 (Figure 1.6). The Gp120 component is a glycoprotein expressed on 
the surface of HIV virions and infected host cells, while the Gp41 component is a transmembrane protein. 
Gp120 dissociates from Gp41 and a Gp41 fusion peptide is inserted into the host cell membrane. The 
virus and host membranes subsequently fuse and the capsid and its contents are released into the 
cytoplasm of the host cell (Figure 1.7) (Nisole and Saïb, 2004; Sorin and Kalpana, 2006; Maartens, 
Celum and Lewin, 2014; Campbell and Hope, 2015).  
Reverse transcription, trafficking and uncoating:  After the release of the capsid into the cytoplasm of 
the host cell, reverse transcription occurs, where the viral enzyme, reverse transcriptase, converts the 
single stranded viral RNA into double stranded DNA (Campbell and Hope, 2015). The accessory protein, 
Vif, is involved in the stimulation of reverse transcription (Li et al., 2005). While the viral RNA is being 
reverse-transcribed, the capsid is trafficked towards the nucleus, commandeering the host cell 
cytoskeleton and making use of its microtubules, microfilaments and molecular motors (Gaudin et al., 
2013). At this point, the capsid is thought to serve two main purposes: firstly, to maintain reverse 
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transcriptase and viral RNA in a closed environment and secondly, to protect the viral genome from host 
cell defences (Campbell and Hope, 2015). The viral capsid eventually disassembles, a process termed 
uncoating, which results in the formation of sub-viral particles named reverse-transcription complexes 
(RTCs) while reverse transcription is ongoing and subsequently pre-integration complexes (PICs) (Figure 
1.7). HIV PICs are high molecular weight nucleoprotein complexes that comprise the double-stranded 
reverse-transcribed viral DNA associated with several known and unknown cellular and viral proteins 
including viral matrix proteins and the enzymes reverse transcriptase and integrase as well as Vpr, which 
plays a role in the eventual nuclear import of the PIC (Nisole and Saïb, 2004; Li et al., 2005; Sorin and 
Kalpana, 2006; Campbell and Hope, 2015). HIV-1 Nef and Vif and the cellular protein cyclophilin A are 
associated with the incoming capsid and seem to affect reverse-transcription and/or uncoating (Nisole 
and Saïb, 2004). Additionally, Vif has been shown to bind to APOBEC3G, a cytidine deaminase nucleic 
acid-editing enzyme which forms part of an antiviral pathway in human T lymphocytes, and targets it for 
degradation by the proteasome (Marin et al., 2003). Nef also seems to have modulating effects on host 
anti-HIV immune responses by downregulating certain cellular receptors, including CD4, MHCI, MHCII 
and CD28. The downregulation of MHC I is believed to protect HIV-infected cells from the host cell‟s 
cytotoxic T cell response, while CD4 down-regulation probably limits the adhesion of HIV-infected T cells 
to antigen-presenting cells, preserving the movement of these infected cells into the circulation and 
consequently the spread of the virus. An additional explanation for CD4 down-regulation is that it 
guarantees no interaction between CD4 receptors of the already infected cell and the Gp160 proteins of 
new virions budding from it. In this way, CD4 downregulation contributes to Nef‟s role in enhancing viral 
infectivity (Li et al., 2005). The uncoating process is not yet fully understood and three possible 
mechanisms have been proposed by which it might occur. The immediate uncoating theory maintains that 
capsid uncoating takes place very soon after the HIV-1 virion fuses with the host cell plasma membrane. 
Cytoplasmic uncoating theory postulates that capsid disassembly happens in the cytoplasm and that a 
reasonable amount of viral capsid proteins remains associated with the RTC. The nuclear pore complex 
(NPC) uncoating theory describes the capsid as remaining intact until it arrives at the NPC of the host 
cell. NPCs are supramolecular protein structures that traverse the nuclear membrane, protruding from the 
cytoplasm into the nucleoplasm. The NPC uncoating theory allows for the capsid to protect the replicating 
viral genome all the way from the cell membrane up to the nuclear membrane (Campbell and Hope, 
2015). 
Nuclear import and integration:  When the PIC, which now contains the double stranded viral genome, 
arrives at the nuclear membrane, it is translocated into the nucleus via NPCs (Nisole and Saïb, 2004). 
This trafficking process is largely dependent on the viral capsid protein (Campbell and Hope, 2015). Viral 
Protein R is also involved and it is known to interfere with host cell cycle progression and can induce 
apoptosis (Li et al., 2005). The PIC then integrates its double stranded genome into the host cell DNA 
utilising a reaction catalysed by the viral enzyme integrase (Sorin and Kalpana, 2006; Gaudin et al., 
2013).  
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Late Phase 
 
Figure 1.8: Late phase of the HIV-1 life cycle (Freed, 2015)   
 
Transcription, export and translation:  Once the viral genome has been integrated into the host cell 
DNA, it is transcriptionally activated by the viral regulatory protein Tat. In conjunction with  host cellular 
transcription factors, Tat enhances the transcription and replication of the integrated proviral DNA to 
enable maximal transcription of the viral genes into RNA (Sorin and Kalpana, 2006; Debaisieux et al., 
2012). Once the new viral RNA molecules have then been formed within the nucleus, they are exported 
to the cytoplasm where they are translated to produce Gag polyprotein precursors, GagPol polyprotein 
precursors, viral envelope glycoproteins, as well as the regulatory and accessory viral proteins. The Gag 
polyprotein precursor contains matrix, capsid and nucleocapsid domains, while the GagPol polyprotein 
precursor additionally includes the viral enzyme domains (Figure 1.8). The viral proteins necessary for 
the construction of the new virion are encoded for by spliced viral RNA molecules, while un-spliced viral 
RNA gets packaged into the new capsid (Sorin and Kalpana, 2006; Freed, 2015). The regulatory viral 
protein Rev is involved in the nuclear export of un-spliced viral RNA (Li et al., 2005). 
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Trafficking and assembly:  The assembly of the new virus particle takes place at the host cell plasma 
membrane and its various components, including newly synthesized viral RNAs and precursor proteins, 
are transported here by the host cell microtubule network and associated motors (Gaudin et al., 2013). 
Gp160 envelope glycoproteins (Env) travel via the secretory pathway: from the nucleus, through the 
endoplasmic reticulum, to the golgi apparatus and then in vesicles to the plasma membrane (Figure 1.8) 
(Freed, 2015). The new virion assembly process constitutes Gag multimerization, the binding of these 
Gag multimers to viral genomic RNA and the formation of complexes, including the Gag-Gag/Pol complex 
as well as larger subsequent complexes containing the viral proteins and various host cell proteins 
required for assembly and budding (Sorin and Kalpana, 2006). The viral structural protein domains 
perform various functions in this regard. Matrix protein domains target Gag to the plasma membrane and 
promote the incorporation of Env glycoproteins into the forming virions, while capsid domains drive the 
Gag multimerization and nucleocapsid domains recruit viral RNA for the new virion‟s genome (Freed, 
2015).  
Budding and maturation:  Finally, the assembled virus particle must undergo a membrane fission event 
and bud off from the producer cell, incorporating the host plasma membrane as its viral envelope while 
doing so (Sorin and Kalpana, 2006; Freed, 2015). The viral accessory protein Vpu is involved in 
enhancing the release of the progeny virions from infected cells. It is a membrane protein that, similar to 
Nef, aids in the degradation of the CD4 receptor in HIV-infected lymphocytes. Additionally, it has the 
ability to form ion channels in cell membranes. These mechanisms enable Vpu to counteract host cell 
factors that hamper the release of progeny virions from infected cells (Li et al., 2005; Guatelli, 2009). Vpu 
also acts as an antagonist to the host innate immune response. In lymphocytic cell lines, it has been 
shown that the increased expression of intercellular adhesion molecule 1 (ICAM-1) mRNA observed in 
these cells upon HIV-1 infection is counteracted by Vpu. Vpu causes a downregulation of ICAM-1 and 
subsequently a decrease in the formation of conjugates between infected CD4-positive T cells and NK 
cells resulting in a reduction in the NK cell-mediated killing of HIV-infected T cells (Sugden, Pham and 
Cohen, 2017). The viral enzyme, protease, eventually cleaves the Gag polyprotein allowing virion 
maturation to occur. Once the  individual Gag domains are liberated, the capsid proteins assemble to 
form the conical capsid core and the other structural proteins to form  the mature virion (Sorin and 
Kalpana, 2006; Freed, 2015) (Figure 1.8). 
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1.4. ANTIRETROVIRAL THERAPY (ART) 
Current antiretroviral therapy cannot cure HIV-1 – a consequence of the pool of latently infected CD4 T 
cells created during early infection – and lifelong chronic and continuous ART is the gold standard of HIV- 
management. Antiretroviral drugs do however limit HIV-associated morbidity and mortality as well as 
reduce transmission-rates. Sustained ART-mediated suppression of plasma viral loads conserves and 
restores immune system function, prevents the development of drug-resistance, and may additionally 
contribute to lessening the virus-associated immune activation and inflammation thought to augment the 
progression to AIDS. (Cihlar and Fordyce, 2016). ART counteracts the HIV-1 virus by blocking its 
replication at multiple stages in the virus life-cycle and these drugs are divided into five classes according 
to where they act  (Maartens, Celum and Lewin, 2014) (Table 1.3).  
Table 1.3: An overview of current antiretroviral drugs and their actions. Content from Arts and 
Hazuda (2012). 
 Antiretroviral Drugs and their Actions  
Class Action Drugs 
Nucleoside-analogue Reverse 
Transcriptase Inhibitors (NRTIs) 
NRTIs are analogues of nucleoside 
substrates which interfere with the 
reverse transcription of single-stranded 
viral RNA into double-stranded viral 
DNA by arresting the assembly of the 
viral DNA chain. 
Abacavir 
Didanosine 
Emtricitabine 
Lamivudine 
Stavudine 
Zidovudine 
Tenofovir (a nucleotide 
RT inhibitor) 
Non-nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTIs) 
NNRTIs bind to a noncatalytic allosteric 
pocked on the viral enzyme, reverse 
transcriptase, altering its activity which 
inhibits the generation of double-
stranded viral DNA from single-stranded 
viral RNA. 
Etravirine 
Delavirdine 
Efavirenz 
Nevirapine 
Integrase Inhibitors 
Inhibit the integration of viral DNA into 
the host cellular DNA. 
Raltegravir 
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Protease Inhibitors (PIs) 
PIs inhibit the cleavage of Gag and 
Gag-Pol precursor proteins by the viral 
enzyme protease into mature proteins.  
Amprenavir 
Atazanavir 
Darunavir 
Fosamprenavir 
Indinavir 
Lopinavir 
Nelfinavir 
Ritonavir 
Saquinavir 
Tipranavir 
E
n
tr
y
 
In
h
ib
it
o
rs
 Fusion Inhibitors Entry Inhibitors disrupt various steps in 
the process of virion fusion with the host 
cell and the subsequent release of the 
virus core into the host cytoplasm. 
Enfuvirtide  
Coreceptor Antagonists Maraviroc 
 
 
1.4.1 Highly Active Antiretroviral Therapy (HAART) 
HAART (also referred to as combination ART) is a combination of three or more antiretroviral drugs (Carr 
and Cooper, 2000) and initial therapy usually consists of two Nucleoside-analogue Reverse Transcriptase 
Inhibitors (NRTIs) combined with a third drug, often a non-nucleoside reverse transcriptase inhibitor 
(NNRTI),  or an integrase inhibitor or protease inhibitor (PI). Originally, patient HAART regimens were 
initiated based on decreasing CD4 cell counts or clinical indications of AIDS. However, recently therapy is 
often commenced immediately after a positive HIV-diagnosis (Cihlar and Fordyce, 2016). Current World 
Health Organisation (WHO) guidelines strongly recommend that ART should be initiated in all adults living 
with HIV regardless of their clinical stage and CD4 cell count (World Health Organization, 2016). 
1.4.2 Adverse Events 
Unstructured ART interruptions have been associated with an increased risk of mortality, opportunistic 
infections, virologic failure, treatment resistance and limited immunological recovery. Unfortunately 
treatment interruptions are common and result in poorer patient outcomes (Kranzer and Ford, 2011). 
Drug-related adverse events often contribute to treatment interruption. A meta-analysis by Al-Dakkak et 
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al., (2013) found that ART-related adverse events decreased treatment adherence and that the effect and 
magnitude thereof varied between the specific adverse events. These authors purport that managing 
adverse events can improve medication adherence, and therefore, decrease viral resistance to therapy, 
patient progression to AIDS and mortality.  
Short Term Adverse Events 
Short term ART-associated adverse events include gastrointestinal toxicities, drug hypersensitivity 
reactions, central nervous system toxicity and lactic acidosis. Gastrointestinal toxicity is one of the primary 
treatment limiting adverse events for PIs and it can manifest as nausea, vomiting and diarrhoea. 
Hypersensitivity reactions to some antiretroviral drugs do occur and can potentially be fatal: should a 
patient be re-exposed to the offending drug anaphylaxis can ensue. Central nervous system toxicity is 
frequently associated with the NNRTI, Efavirenz and this can include vivid dreams, balance problems, 
drowsiness as well as dizziness (Hawkins, 2010). One of the most serious short term adverse events of 
ART is lactic acidosis, which has been linked to mitochondrial toxicity (Carr and Cooper, 2000). Other 
common short-term side-effects include fatigue, dizziness and dyspepsia as well as rash. Anaemia and 
jaundice can also occur  (Hawkins, 2010). 
Long Term Adverse Events 
The long-term use of some ARTs has been associated with hepatotoxicity as well as renal adverse 
events. The drug Tenofovir, especially, has been linked to renal dysfunction (Hawkins, 2010). Distal 
sensory peripheral neuropathy which subjectively manifests as numbness and/or pain in the extremities 
has also been described following long-term exposure to certain ARTs and could be the result of 
mitochondrial toxicity and impaired ATP synthesis (Hawkins, 2010). An important long-term complication 
of ART use is an increased risk for CVD, which has especially been reported in the context of 
lipodystrophy, another long-term adverse event associated predominantly with the use of certain NRTIs 
and PIs (Flint et al., 2009; Hawkins, 2010). The primary clinical features of lipodystrophy are peripheral fat 
loss and central and dorsocervical fat accumulation. Metabolic features of this adverse event include 
hypertriglyceridaemia, hypercholesterolaemia, insulin resistance and type II diabetes mellitus. These 
metabolic abnormalities are also more prevalent in individuals receiving PI treatment (Flint et al., 2009; 
Villarroya, Domingo and Giralt, 2010). 
1.4.3 Fixed Dose Combination (FDC) 
Recently, the use of once-daily fixed-dose combination drugs (FDC) has become popular due to a 
decrease in regimen complexity consequent to smaller pill burdens and less frequent dosing. This, 
together with the enhanced drug tolerability of modern regimens, has allowed for improved initial ART 
regimen durability (Willig et al., 2008). Presently, the WHO strongly recommends that FDC and once-daily 
regimens are used as the preferred mode of antiretroviral treatment. First-line FDC for adults should 
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consist of two NRTIs plus an NNRTI or an integrase inhibitor. The preferred option to initiate ART is 
tenofovir (TDF) with lamivudine (3TC) or emtricitabine (FTC) and efavirenz (EFV) as a fixed-dose. 
Second-line ART in adults should consist of an NRTI backbone together with a ritonavir-boosted protease 
inhibitor. The favoured FDC NRTI backbone approach is the use of zidovudine (AZT) and 3TC (World 
Health Organization, 2016). 
 
1.5. HIV, ART AND CVD 
The scope of the cardiovascular risk associated with HIV/ART has reached a point where there is 
controversy regarding what offers the bigger cardiovascular threat – living with HIV or being on ART 
(Wang et al., 2015). In the “Data Collection on Adverse Events of Anti-HIV Drugs (DAD)” study, a large, 
on-going cohort study of HIV-infected patients on treatment, a significant association was observed 
between the period of ART exposure and the risk of myocardial infarction. The study findings also 
suggest that this risk varies according to the ART drug class, with a significant increase in myocardial 
infarction risk being attributed to PIs. However, this might have partly been a consequence of the adverse 
effects of these drugs on serum lipids (Reiss et al., 2007). PIs have also been connected to higher IL-6 
levels, compared to efavirenz (Borges et al., 2015) (For more information on the involvement of 
inflammatory cytokines in HIV and ART, view my review paper in Appendix A). Furthermore, HIV-infection 
per se is characterised by continuous immune activation, which is maintained even upon receiving ART, 
and inflammation is considered a pivotal mechanism responsible for the high levels of CVD in the HIV-
infected population (Hunt, 2012). The sustained immune activation observed in HIV-infection has been 
attributed to ongoing viral replication; coinfections (especially chronic viral infections); the translocation of 
microbial by-products across a dysfunctional gut mucosa; decreases in immunoregulatory cells and 
immune structure damage (Deeks, 2011; Younas et al., 2016). Moreover, HIV-infected persons receiving 
ART are at a greater risk for certain age-linked diseases, such as CVD, and some scholars even consider 
HIV to be associated with premature ageing, which has been attributed, in part, to the immune 
dysfunction observed in this infection (Deeks, 2011). Additionally, dyslipidaemia and impaired cholesterol 
metabolism, which are both involved in the atherosclerotic process, are possibly enhanced by HIV and 
ART (Mu et al., 2007; Crowe et al., 2010). 
Given the many cardiovascular and other adverse effects of ART, the “Strategies for Management of 
AntiRetroviral Therapy (SMART)” trial investigated whether a CD4-positive T-cell count-guided use of 
antiretrovirals, would be more beneficial compared to lifelong continuous use, yet, contrary to 
expectations, they noted an increase in the rate of adverse cardiovascular events associated with the 
interruption of ART (Phillips et al., 2008). The accumulating evidence for an interplay between HIV, ART 
and CVD (Figure 1.9) makes the fact that in 2015 17.0 million people worldwide were living with HIV and 
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receiving treatment (UNAIDS, 2016) disconcerting, as this represents a very large population of CVD-
vulnerable individuals. Consequently, this warrants zooming-in on the mechanisms involved in this 
double-burden of disease, in order to devise customised treatment strategies for HIV-positive individuals 
with increased cardiovascular risk. 
 
Figure 1.9: Schematic diagram of the interplay between HIV, ART and CVD. Via multiple and 
complex pathways, all cardiovascular risk factors seem to influence endothelial cell functioning and 
oxidative stress appears to act as the central causal mechanism. Increased reactive oxygen species 
(ROS) lead to oxidative stress, which reduces nitric oxide (NO) bioavailability. This results in endothelial 
dysfunction and increased cardiovascular risk. Figure designed by the author of this thesis. 
1.5.1 HIV, ART and Endothelial Dysfunction 
As the pathophysiological process believed to be at the heart of CVD, it makes it unsurprising that 
endothelial dysfunction has been linked to HIV/AIDS and ART as well. Perinatally infected HIV-positive 
adolescents were shown to have higher levels of endothelial dysfunction compared to their behaviourally-
infected peers, possibly due to a longer cumulative duration of HIV/ART exposure (Dirajlal-Fargo et al., 
2017). Asymmetric dimethylarginine (ADMA), a marker of endothelial dysfunction, levels were raised in 
HIV-infected individuals compared with HIV-negative controls. Levels were also higher in HIV-positive 
individuals receiving ART compared with untreated HIV-positive persons. In untreated HIV-infection, viral 
replication was independently associated with endothelial dysfunction (Haissman et al., 2016). 
Pronounced coronary endothelial dysfunction was present in HIV-positive patients without significant 
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coronary artery disease (CAD) – as severe as that observed in HIV-negative clinical CAD patients 
(Iantorno et al., 2017). 
However, whether or not HIV directly infects vascular endothelial cells in vivo has been described as 
controversial (Kline and Sutliff, 2008), with some reviewers arguing that this is indeed the case (Lambert 
et al., 2016), whilst others have been more cautious (Maartens, Celum and Lewin, 2014). Currently, the 
accepted explanation with regards to HIV/AIDS-associated endothelial dysfunction is that both HIV-
proteins and components of ART act as causal agents. The vascular endothelium of an HIV-infected 
individual is continuously exposed to these stimuli via the bloodstream which interfere with endothelial cell 
signalling pathways. A primary consequence of this seems to be a decrease in NO bioavailability, 
possibly due to increased ROS generation and oxidative stress, propelling the vascular endothelium into 
a dysfunctional state (Kline and Sutliff, 2008; Lambert et al., 2016). 
1.5.2 HIV-1-Proteins and Endothelial Dysfunction 
Tat 
HIV-1 Tat has the ability to enter the host cell‟s nucleus and, additionally, it can be actively secreted by 
infected cells and imported by various other cells, including endothelial cells (Debaisieux et al., 2012). Tat 
has been associated with many of the features of endothelial dysfunction, including increased ROS 
production, enhanced endothelial cell permeability and adhesion molecule expression.  
Contact with Tat in rat brain endothelial cells, triggered a significant increase in oxidative stress (Price et 
al., 2005). In human pulmonary artery endothelial cells, Tat‟s ability to induce ROS production seemed to 
be linked to the activation of NFĸB. In these cells, Tat exposure induced the expression of vascular cell 
adhesion molecule 1 (VCAM-1), which might have been mediated by ROS production, p38 mitogen-
activated protein kinase (MAPK) activation and the nuclear translocation of NFĸB (Liu et al., 2005). Tat 
treatment of human umbilical vein endothelial cells resulted in monocyte adhesion via increased ICAM-1 
expression. This also occurred via activation of the MAPK pathways and eventual NFĸB nuclear 
translocation (Duan et al., 2013). 
Tat has been shown to alter tight junction proteins in brain endothelial cells, increasing their permeability. 
In these cells in culture, Tat decreased the expression of claudin-1, claudin-5 and zonula occludens-2  
(ZO-2) (Andras et al., 2003) as well as occludin mRNA and protein levels, firstly by inhibiting its 
expression and secondly by cleaving it via matrix metalloproteinase-9 (Xu et al., 2012). Together, Tat and 
pro-atherogenic shear stress synergistically increased the endothelial cell expression of cathepsin K, a 
protease which has been associated with coronary artery disease (Cheng et al., 2013), in cultured human 
aortic endothelial cells and HIV-transgenic mice (Parker et al., 2014). Moreover, in primary human lung 
microvascular endothelial cells, Tat was found to cause apoptosis following the activation of caspase-3 by 
a pathway distinct from the established Fas-ligand or TNF extrinsic pro-apoptotic pathways (Park et al., 
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2001). Caspase-3 is the most important executioner caspase and the two main apoptotic pathways 
(extrinsic and intrinsic) as well as the perforin/grandzyme pathway all culminate in its activation via 
cleavage by various initiator caspases (Elmore, 2007). 
Gp160 
Like Tat, Gp160, especially its Gp120 component, has been linked to endothelial dysfunction. It has been 
shown to reduce eNOS levels and increase oxidative stress as well as endothelial barrier permeability 
(Price et al., 2005; Kanmogne et al., 2007; Yang et al., 2009; Jiang et al., 2010). In porcine coronary 
artery rings pre-treated with the inflammatory cytokine, TNF-α, exposure to Gp120 significantly decreased 
endothelium-dependent vasorelaxation compared to untreated controls. eNOS mRNA levels and protein 
expression were also significantly reduced in these porcine coronary rings as well as in cultured human 
coronary artery endothelial cells (Jiang et al., 2010). Exposure to Gp120 was shown to cause a significant 
increase in oxidative stress in rat brain endothelial cells (Price et al., 2005). In human brain microvascular 
endothelial cells, Gp120 up-regulated interleukin-6 (IL-6) and interleukin-8 (IL-8) expression, which 
resulted in the adhesion and migration of monocytes across in vitro blood brain barrier models (Yang et 
al., 2009). Gp120 was also shown to activate protein kinase C, which resulted in increased intracellular 
calcium release. This led to cytoskeletal changes, including the disruption of tight junctions, and ultimately 
decreased blood brain barrier tightness, causing increased monocyte migration across the barrier 
(Kanmogne et al., 2007). 
Nef 
Nef interferes with host cell signal transduction as well as the regulation of cholesterol trafficking (Li et al., 
2005). Additionally, it has the ability to enter endothelial cells and while the mechanism by which it 
achieves this remains to be elucidated, it has been associated with nocuous consequences, such as 
atherosclerotic chemokine release, ROS formation, mitochondrial dysfunction and apoptosis (Duffy et al., 
2009; Wang et al., 2014). In Jurkat T cell- and THP1 monocyte cell lines, Wang et. al. (2014) showed that 
Nef could independently induce its own transfer from these cells to cultured human coronary artery 
endothelial cells utilising a mechanism that involved direct cell to cell contact. Furthermore, once in these 
cells, Nef induced endothelial activation, dysfunction and apoptosis via an NADPH oxidase and ROS-
dependent mechanism. Nef-exposure also induced the release of monocyte chemoattractant protein-1 
(MCP-1) in an NFĸB dependent manner.  
After being incubated in solutions supplemented with various concentrations of Nef for 24 hours, 
endothelium-dependent vasorelaxation in porcine pulmonary artery rings was significantly reduced. 
Furthermore, Nef exposure caused a significant increase in superoxide production in cultured human 
pulmonary artery endothelial cells (HPAECs) as well as porcine pulmonary arteries, resulting in oxidative 
stress. In cultured porcine pulmonary artery endothelial cells and HPAECs, Nef was also shown to reduce 
eNOS expression (Duffy et al., 2009). In two mouse models of atherosclerosis, injecting the animals with 
Stellenbosch University  https://scholar.sun.ac.za
28 
 
recombinant Nef led to dyslipidaemia as well as the accumulation of cholesterol in macrophages in their 
vessel walls (Cui et al., 2014). Given the above, Nef undoubtedly contributes to the development of 
endothelial dysfunction, and by extension atherosclerosis.  
Vpu and Vpr 
The endothelial effects of Vpu and Vpr have not been widely researched and currently much remains to 
be elucidated. In an in vitro experiment, where cultured human umbilical vein endothelial cells were 
infected with recombinant adenoviruses expressing individual HIV-proteins, cultured B-lymphocyte cells 
solely adhered to Vpu-expressing endothelial cells. This was ascribed to Vpu‟s ability to upregulate 
endothelial CD40, which led to the efficient expression of VCAM-1 (Henderson et al., 2004). In primary 
human brain microvascular endothelial cells, Vpr treatment induced apoptosis, an effect that was 
synergistically enhanced by ethanol co-treatment (Acheampong et al., 2002). 
1.5.3 Common Antiretroviral Drugs and Endothelial Dysfunction 
Common First-line FDC Drugs 
First-line therapy is treatment considered optimal for the initial treatment of a condition or disease (AIDS 
info, 2018). In South Africa government roll-out first-line FDC consists of two NRTIs, Tenofovir (TDF) and 
Emtricitabine (FTC), and one NNRTI, Efavirenz (EFV). EFV is the NNRTI that has most widely been 
researched in terms of its endothelial effects and an association with endothelial dysfunction has been 
established (Gupta et al., 2012; Faltz et al., 2017). EFV significantly augmented monolayer permeability 
in an in vitro study of human coronary artery endothelial cells, which was associated with decreased tight 
junction protein expression, including ZO-1, claudin-1, occludin and JAM-1. These effects were mediated 
by an increase in ROS generation and the activation of JNK and NFĸB (Jamaluddin et al., 2010). In 
human cerebral microvascular endothelial cells as well as in mice, EFV was shown to affect endothelial 
cell integrity. Exposure to the drug decreased levels of the tight junction protein, claudin-5, and increased 
endothelial permeability (Bertrand, Dygert and Toborek, 2016). Treating human umbilical vein endothelial 
cells with EFV resulted in an increase in ROS and this was associated with the induction of heat-shock 
proteins, endoplasmic reticulum stress as well as autophagy (Weiß et al., 2016). Autophagy controls 
cellular protein and organelle degradation. It is a highly conserved cellular pathway involved in survival, 
development and homeostasis (Yang and Klionsky, 2010). Endothelial cells in the brain microvessels of 
HIV transgenic mice on continuous EFV treatment showed endoplasmic reticulum (ER) stress associated 
with decreased autophagy. The same correlation was observed in human blood brain barrier cells, 
including cultured cerebral microvascular endothelial cells, which was somewhat unexpected as ER 
stress is generally associated with increased autophagic activity (Bertrand and Toborek, 2015). 
Considering its effects on blood brain barrier cells, it may thus be unsurprising that, in a retrospective 
cohort study of 445 HIV-positive participants, long-term EFV use was associated with poorer 
neurocognitive outcomes in comparison with Lopinavir boosted with Ritonavir (LPV/r) (Ma et al., 2016). 
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The EFV component of Atripla®, a FDC antiretroviral drug comprising TDF, FTC and EFV, and not TDF 
or FTC, was associated with increased oxidative stress and PARP activity (PARP is involved in DNA 
repair and apoptosis; once cleaved by executioner caspases such as caspase-3, PARP is involved in 
some of the changes noted in apoptotic cells (Elmore, 2007)), as well as increased apoptosis and 
necrosis in cultured endothelial cells. EFV also caused impaired endothelial function in rat aortic rings 
(Faltz et al., 2017). 
Although TDF and FTC are not as well researched as EFV, current evidence suggests that these first-line 
FDC components are not associated with endothelial dysfunction. De Pablo et al. (2012) observed no 
changes in leukocyte-endothelial cell interactions when human umbilical vein endothelial cells and 
leukocytes were treated with TDF and FTC in vitro, both in combination and separately. Additionally, in 
human coronary artery endothelial cells Kim et. al. (2011) found no evidence of any direct effects by TDF 
on the transcription and expression of pro-oxidative stress, proinflammatory or pro-apoptotic genes. 
Common Second-line Antiretroviral Drugs 
Second-line therapy is commenced only when a patient on first-line therapy has experienced virological 
failure despite good adherence or has experienced severe adverse events (National Department of 
Health of South Africa, 2015). Of the common protease inhibitor-components of second-line ART, 
Ritonavir has been most directly associated with endothelial dysfunction. Chai et al. (2005) investigated 
the effects of several HIV protease inhibitors on porcine coronary arteries and significant vasomotor 
dysfunction was observed, as well as decreased eNOS expression and increased superoxide anion 
production, with Ritonavir (RTV) accounting for the more potent effects. In porcine pulmonary arteries and 
human pulmonary artery endothelial cells, RTV seemed to cause impaired endothelial function via an 
increment in oxidative stress and reduced eNOS expression. In the porcine pulmonary artery rings, 
contraction and endothelium-dependent relaxation was significantly reduced by RTV in a concentration-
dependent manner. Additionally, subsequent to the RTV treatment, a significant decrease in eNOS 
mRNA and protein levels was shown in cultured human pulmonary artery endothelial cells (Wang et al., 
2009). Ritonavir-boosted protease inhibitors have been shown to augment ROS production, inflammation 
and cell senescence to varying degrees in human coronary artery endothelial cells, as well as causing 
vascular endothelial dysfunction, with the strongest effects detected in cells treated with LPV/r. Both 
eNOS expression and NO production were hampered by LPV/r, while the expression of endothelin-1 (an 
endothelium-derived vasoconstrictor) was increased. The secretion of soluble ICAM or soluble VCAM, 
which is indicative of altered cell integrity, was increased 2-3 times by LPV/r (Auclair et al., 2014). 
Contrary to the aforementioned in vitro studies, however, a study exploring the effects of LPV/r in healthy, 
non-obese human subjects, showed no evidence of endothelial dysfunction (Dubé et al., 2008). Besides 
the direct endothelial effects of RTV, the drug can possibly also contribute to endothelial dysfunction in a 
more indirect way, since it has additionally been linked to serum lipid changes, a known contributor to 
endothelial dysfunction. In a cohort of HIV-negative participants, 100 mg of Ritonavir taken two times a 
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day significantly increased total cholesterol, LDL cholesterol, total cholesterol/HDL cholesterol ratio and 
triglycerides and reduced HDL cholesterol (Shafran, Mashinter and Roberts, 2005). Human subjects from 
a study conducted in Ethiopia exhibited elevated cholesterol, total cholesterol/HDL cholesterol ratio and 
triglycerides as well as elevated markers of inflammation leading the researchers to suggest that current 
EFV and LPV/r ART regimens might play a role in the development of HIV-associated preclinical 
atherosclerosis (Gleason et al., 2015).  
 
1.6. A SOUTH AFRICAN PERSPECTIVE 
South Africa presents a unique challenge to healthcare providers. HIV prevalence is disproportionally 
high, and the incidence of CVD is on the rise. In 2010 38.9% of age-standardised death rates in South 
Africa were due to non-communicable diseases and of these 287/100000 were accounted for by CVDs 
(Nojilana et al., 2016). In fact, non-communicable diseases including CVDs, type II diabetes mellitus and 
cancer have been growing in the whole Sub-Saharan region (Dalal et al., 2011). Statistics South Africa 
reports that of the total deaths in 2014, cerebrovascular disease ranked second as the leading underlying 
cause of death after tuberculosis, followed by diabetes mellitus. HIV and other forms of heart disease 
ranked fifth and sixth respectively (Statistics South Africa, 2015). According to the WHO, Sub-Saharan 
Africa is the region most affected by HIV, where 25.6 million people were living with the virus in 2015, and 
it accounts for two-thirds of the global total of new infections as well (WHO, 2018). In South Africa in 
2012, “The National HIV Prevalence, Incidence and Behaviour Survey” found the overall HIV-prevalence 
to be 12.2%, with women being more affected than men at 14.4% versus 9.9%. The highest prevalence-
group was adults aged 25 – 49 years at a shocking 25.2% (Zuma et al., 2016).  
The abovementioned statistics make the HIV/AIDS-CVD intersection an area of mounting concern. A 
systematic literature review by Hyle et al. (2017) found that data on people living with HIV/AIDS (PLWHA) 
in Sub-Saharan Africa suggested an increased risk of early atherosclerosis and stroke. Furthermore, they 
noted that traditional cardiovascular risk factors were also prevalent in the general population, which 
could indicate that PLWHA may additionally have multiple cardiovascular risk factors, increasing their 
overall risk of CVD. An ecological study found that Sub-Saharan countries with higher HIV incidence had 
a higher prevalence of hypertension when adjusted for age, sex, year of study, markers of socioeconomic 
development and ART coverage (Angkurawaranon et al., 2016). Worryingly, however, Rabkin et al. 
(2015) report that although patients were adherent with chronic HIV treatment, screening for and 
management of cardiovascular risk factors were suboptimal at a Free State Community Health Centre in 
South Africa. Furthermore, whilst South Africa has managed to scale-up ART coverage, there have been 
perturbing increases in many HIV-related risk behaviours (Zuma et al., 2016) (Table 1.4).  
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Table 1.4: Key findings from “The National HIV Prevalence, Incidence and Behaviour Survey, 
2012”. Data obtained from Zuma et al. (2016).  
 2008 2012  
HIV prevalence 10.6% 12.2% ↑ 
ART exposure 16.6% 31.2% ↑ 
Multiple sexual partners in the previous 12 months 11.5% 18.3% ↑ 
Condom use 45.1% 36.2% ↓ 
Knowledge about HIV transmission and prevention 31.5% 26.8% ↓ 
 
 
1.7. CONCLUDING REMARKS 
The increased cardiovascular risk observed in HIV/AIDS creates a unique double-burden of disease and 
given the exceedingly high HIV-prevalence in South Africa, this is an area that warrants the attention of 
government, clinicians and researchers alike. Investigating the cellular mechanisms involved in the HIV-
ART-CVD interplay is thus of utmost importance, especially in a manner customized for the South African 
setting. Antiretroviral drugs commonly used in government roll-out programmes and their effects on the 
vascular endothelium in the context of HIV provide a key area of research in the quest to elucidate the 
underlying causes of this burgeoning double epidemic. 
 
1.8. PROBLEM IDENTIFICATION AND STUDY AIMS 
1.8.1 Problem Identification 
The association between HIV, ART and CVD, has been well established (Phillips et al., 2008; Islam et al., 
2012; Hyle et al., 2017) and numerous studies point to endothelial dysfunction as the possible underlying 
cause (Francisci et al., 2009; Ross et al., 2009; Baker et al., 2012; Gupta et al., 2012; Pirro et al., 2016; 
Dirajlal-Fargo et al., 2017). However, the mechanisms involved appear to be multiple and complex, with 
many of the endothelial cell signalling pathways affected remaining to be elucidated.  
Sub-Saharan Africa is the region most affected by the global HIV-pandemic (WHO, 2018), making it 
imperative that research into the cellular mechanisms involved in the interplay between HIV, ART and ED 
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is tailored for this region, especially with regards to the specific antiretroviral drugs used in government 
roll-out programmes. In South Africa first-line FDC government roll-out antiretroviral drugs include TDF, 
FTC and EFV, and of these EFV has been shown to negatively impact endothelial functioning (Gupta et 
al., 2012; Faltz et al., 2017). Second-line treatment usually includes the protease inhibitors Lopinavir 
(LPV) and RTV of which RTV has been associated with endothelial dysfunction (Chai et al., 2005; Wang 
et al., 2009). These associations with endothelial dysfunction need further investigation to elucidate the 
mechanisms involved. An understanding of how these drugs contribute to endothelial dysfunction within 
the context of HIV will aid clinicians in tailoring treatment regimens for patients who present with 
increased cardiovascular risk. Therefore, the pathophysiological mechanisms associated with these 
antiretroviral drugs commonly used in South African government roll-out programmes were investigated in 
endothelial cells within an in vitro simulated HIV-microenvironment.  
1.8.2 Main Study Aim 
To investigate the effects of first line antiretroviral drug components (a combination of the NRTI/NNRTIs 
efavirenz, emtricitibine and tenofivir, commonly found in FDC in South Africa), and second -line 
antiretroviral drug components (the PIs lopinavir and ritonavir) on aortic endothelial cell (AEC) function – 
a mechanistic in vitro approach. 
Objective 1 
To develop an in vitro HIV-1-model by supplementing endothelial growth medium with HIV-proteins. This 
objective encompassed determining the optimal HIV-protein concentrations and exposure time of AECs 
to this HIV-protein-medium (time- and concentration-response investigations) needed for maximal 
observed differences compared to untreated controls, with regards to cell viability, NO production and 
nitrosative stress.   
Objective 2 
To determine the AEC effects of NRTI/NNRTI treatment within an HIV-protein-medium environment (as 
optimised in objective 1) on cell viability, nitric oxide production and nitrosative stress. This objective 
encompassed determining the optimal NRTI/NNRTI treatment concentrations (concentration-response 
investigations) needed for maximal observed differences compared to untreated controls. 
Objective 3 
To determine the AEC effects of PI treatment within an HIV-protein-medium environment (as optimised in 
objective 1) on cell viability, nitric oxide production and nitrosative stress. This objective encompassed 
determining the optimal PI treatment concentrations (concentration-response investigations) needed for 
maximal observed differences compared to untreated controls. 
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Objective 4 
To determine the effects of HIV-protein-medium (as optimised in objective 1) as well as NRTI/NNRTI 
treatment (as optimised in objective 2) and PI treatment (as optimised in objective 3) within HIV-protein-
medium and normal endothelial growth medium on the expression and phosphorylation of important 
vascular signal transduction proteins in cultured AECs, including eNOS, PKB/Akt (an upstream activator 
of eNOS), IκBα (an  inhibitor of the pro-inflammatory transcription factor, NFκB), p22phox (a subunit of 
the ROS-producing enzyme, NADPH-oxidase), nitrotyrosine (indicative of peroxynitrite and nitrosative 
stress), cleaved caspase-3 (the activated form of this important executioner caspase involved in 
apoptosis) and cleaved PARP (involved in apoptosis and cleaved by executioner caspases such as 
caspase-3). 
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CHAPTER 2: METHODS 
 
2.1. AORTIC ENDOTHELIAL CELL CULTURE 
A rat aortic endothelial commercial cell line was selected to investigate the endothelial effects of various 
common South African government roll-out first- and second-line antiretroviral drugs within an in vitro 
HIV-1-model. 
2.1.1 Materials 
 Adult rat Aortic Endothelial Cells (AECs): Supplied by VEC Technologies (University at Albany 
Foundation, 1 University PI, Rensselaer, NY 12144, USA). 
 Endothelial cell growth medium (EGM-2): Supplied by Lonza Ltd (Clonetics, Cambrex Bio 
Science, Walkersville, USA) and distributed locally by Whitehead Scientific. This was 
supplemented with 2% FBS, heparin, long-chain human insulin-like growth factor (R3-IGF-1), 
recombinant human epidermal growth factor (rhEGF), antibiotic GA 1000 (containing gentamicin 
and amphotericin), vascular endothelial growth factor (VEGF), ascorbic acid, recombinant human 
fibroblastic growth factor B (rhFGF-B) and hydrocortisone from the bullet kit in accordance with 
the manufacturer‟s instructions. The FBS content was further increased to 10% as is the standard 
practice for in vitro research and has additionally been found by our laboratory to provide the 
optimum conditions for culturing AECs. This medium was initially used for culturing AECs for the 
various plate-reader assays. 
 Rat endothelial cell growth medium: Supplied by Cell Applications Inc. (5820 Oberlin Dr Suite 
101, San Diego, CA 92121, USA) and distributed locally by Sigma-Aldrich.  This medium was 
used for culturing AECs for western blotting due to problems with the supplier of the previously 
mentioned medium. 
 All salts used to prepare Phosphate Buffered Saline (PBS) were supplied by Merck, Darmstadt, 
Germany. 
 Attachment factor: Supplied by Gibco® by Life Technologies, Cascade Biologics™, now owned 
by ThermoFisher, Waltham, Massachusetts, USA. 
 Trypsin (0.25%): Supplied by Gibco® by Life Technologies; (now owned by ThermoFisher, 
Waltham, Massachusetts, USA) purchased as a 2.5% solution and diluted with PBS. 
 Foetal bovine serum (FBS): Supplied by Biocom-Biotech, Centurion, South Africa. 
 Dimethyl sulfoxide (DMSO): Supplied by Sigma-Aldrich, St. Louis, Missouri, USA. 
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2.1.2 Methods 
AECs were received from the supplier in culture in 75 mm² flasks and, upon arrival, the medium was 
removed and replaced with fresh EGM-2 endothelial growth medium. Thereafter, flasks were placed in an 
incubator (Forma Series II, Thermo Electron Corporation, Waltham, MA, USA) at 37°C with a 5% CO₂ 
atmosphere and 40 – 60 % humidity and left to grow until confluent. The cells received fresh growth 
medium every second day. Once confluent, AECs were passaged in a 1:2 ratio to yield three generations 
of sub-cultures for future use, named P1 (Parent 1), P2 and P3 (Figure 2.1), which were frozen away in a 
freezing medium (90 % FBS, 5 % growth medium and 5 % DMSO or 900 μl FBS, 5 ml growth medium 
and 5 ml DMSO for 1ml of freezing medium) suspension and stored in liquid nitrogen.  
 
 
 
Figure 2.1: Passaging of AECs received from supplier 
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For experimental purposes, a Parent crytotube would be removed from the liquid nitrogen storage, 
allowed to thaw, given fresh medium and seeded in two gelatine-containing attachment factor coated 35 
mm petri dishes. As soon as the cells reached confluency, they were passaged in a 1:2 ratio (Figure 2.2). 
Note that, depending on the parent generation used (P1, P2 or P3), AECs can only be passaged a limited 
number of times before the cell yield starts diminishing. In this study, a P1 cell line was passaged a 
maximum of seven times, a P2 cell line six times and a P3 cell line five times. The passaging process 
commenced with the cells being washed with PBS and incubated in 0.25% trypsin for approximately 3 
minutes until detached from the attachment factor layer at the bottom of the petri dish. They were then 
transferred to a 15 ml conical tube containing fresh growth medium, as the FBS in the medium 
deactivates trypsin, thus protecting the cells from its protease activity. The cells were then centrifuged for 
3 minutes at 1000 revolutions per minute (rpm) at 4°C. Finally, the supernatant was aspirated, removing 
any remaining trypsin, and the pellet re-suspended in fresh growth medium. This cell-containing medium 
was equally divided amongst new 35 mm petri dishes pre-incubated (for at least 1 hour) with attachment 
factor. 
 
 
Figure 2.2: Passaging of parent AEC cell lines 
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2.2. HIV-1-PROTEIN MEDIUM 
Creating an in vitro HIV-1-model optimised for AECs encompassed the development of an HIV-1-protein 
medium which was subject to time- and concentration-response investigations. Three different 
concentrations of three HIV-proteins that have previously been shown to impact vascular endothelial cells 
– Tat, Gp160 and Nef (Kline and Sutliff, 2008) – at two different durations (24-hours and 48-hours) were 
incorporated into the development of the optimal model.  
2.2.1 Materials 
 Recombinant HIV1 Tat protein (ab83353): Supplied by Abcam (Cambridge, UK) and distributed 
locally by Whitehead Scientific. 
 Recombinant HIV1 Gp120 + Gp41 (ab68127) (Gp 160): Supplied by Abcam (Cambridge, UK) 
and distributed locally by Whitehead Scientific.  
 Recombinant HIV1 Nef protein (ab58914): Supplied by Abcam (Cambridge, UK) and distributed 
locally by Whitehead Scientific. 
2.2.2 Methods 
All HIV-1-proteins were diluted in PBS to create concentrated stock-solutions of each (25 μg/ml, 50 μg/ml 
or 100 μg/ml), which were aliquoted and frozen away at temperatures according to the manufacturer‟s 
guidelines. For experimental purposes, these concentrated HIV-1-protein stock solutions were thawed 
and added to endothelial cell growth medium to create three different final concentrations of HIV-1-
proteins in correspondence with what has previously been reported in the literature (Kline and Sutliff, 
2008). HIV-medium 1 contained 25 ng/ml of each of the three proteins, HIV-medium 2 contained 50 ng/ml 
of each of the three proteins and HIV-medium 3 contained 100ng/ml of each of the three proteins. Since 
the proteins were initially diluted in a PBS vehicle, vehicle control cocktails were created to control for any 
possible cellular effects of the PBS. Each of the three HIV-media were thus matched with a 
corresponding vehicle control cocktail containing endothelial growth medium and PBS – the same 
concentration of PBS as present in its HIV-medium counterpart. For a more detailed description of the 
HIV-1-protein medium and vehicle control cocktail dilutions and their preparation, view Appendix B.  
 
2.3. ANTIRETROVIRAL DRUG TREATMENT 
Antiretroviral treatment experiments consisted of two groups: a nucleoside-analogue reverse 
transcriptase inhibitor/non-nucleoside reverse transcriptase inhibitor (NRTI/NNRTI) treatment group and a 
protease inhibitor (PI) treatment group. The NRTI/NNRTI group contained components used in the 
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current SA Government first-line fixed dose roll out treatment regimen, namely, efavirenz (EFV), tenofovir 
(TDF) and emtricitabine (FTC), and the PI group contained components commonly found in second-line 
regimens, namely, lopinavir (LPV) and ritonavir (RTV). After the HIV-1-model was optimised for AECs, the 
antiretroviral treatment was subject to concentration-response investigations within this HIV-1 
environment.  
2.3.1 Materials 
 Efavirenz (EFV): Supplied by SantaCruz Biotechnology, Dallas, Texas, USA.  
 Tenofovir (TDF): Supplied by SantaCruz Biotechnology, Dallas, Texas, USA. 
 Emtricitabine (FTC): Supplied by SantaCruz Biotechnology, Dallas, Texas, USA. 
 Lopinavir (LPV): Supplied by SantaCruz Biotechnology, Dallas, Texas, USA. 
 Ritonavir (RTV): Supplied by SantaCruz Biotechnology, Dallas, Texas, USA. 
 Dimethyl sulfoxide (DMSO), supplied by Sigma-Aldrich, St. Louis, Missouri, USA. 
 Methanol (MeOH), supplied by Merck, Darmstadt, Germany. 
 Distilled water (dH₂O), supplied by Merck, Darmstadt, Germany. 
2.3.2 Methods 
NRTI/NNRTI Treatment: Efavirenz (EFV), Tenofovir (TDF) and Emtricitabine (FTC) 
Drugs were received in powder form. Upon arrival, EFV was dissolved in methanol (MeOH) and TDF and 
FTC in distilled water (dH₂O) to create concentrated stock solutions (21 mM EFV, 10 mM FTC and 393 
μM TDF). The stocks were aliquoted and frozen away at -20°C for future use. For experimental purposes, 
the drug stocks were further diluted in PBS and then added to the optimised HIV-1-protein medium to 
obtain the desired final dosages in correspondence with what has been used in previous studies (Feng et 
al., 2009; Grigsby et al., 2010). NRTI/NNRTI treatment comprised 5.6 nM EFV, 500 nM TDF and 1.3 μM 
FTC. These dosages were furthermore halved and doubled, allowing for three different NRTI/NNRTI drug 
concentrations to be tested. To control for the vehicles used when dissolving the drugs (the MeOH and 
dH₂O), as well as for the additional PBS vehicle used to dilute the HIV-1-proteins, vehicle control cocktails 
were prepared. Three vehicle control cocktails in total, each controlling for the concentrations of vehicle 
present in the three different NRTI/NNRTI drug dosages, as well as in the HIV-1-protein stock solutions 
were prepared and added to endothelial growth medium. For a more detailed description of NRTI/NNRTI 
treatment and vehicle control cocktail dilutions and their preparation, view Appendix C.  
 
PI Treatment: Lopinavir (LPV) and Ritonavir (RTV) 
The PI drugs arrived in powdered form and were diluted in DMSO, aliquoted and stored as concentrated 
stock solutions (10 mM LPV and 2 mM RTV) at 4°C for future use. For experimental purposes, the stocks 
were added to the HIV-1-protein medium to obtain a final single-dose concentration of 10 μM Lopinavir 
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and 2 μM Ritonavir. The concentrations were based on what was used previously by Noor et al. (2006) 
and, as with the NRTI/NNRTI treatment, concentration responses for half- single- and double doses were 
investigated. To control for the DMSO vehicle used to initially dissolve the drugs, as well as the PBS 
vehicle present in the HIV-1-protein medium, vehicle control cocktails were created by adding DMSO and 
PBS to endothelial cell growth medium ensuring the same final concentrations of DMSO and PBS as 
present in the three different PI treatment concentrations. For a more detailed description of PI treatment 
and vehicle control cocktail dilutions and preparation, view Appendix C.  
 
2.4. PLATE READER ANALYSES 
A plate reader (FLUOstar Omega, serial no: 415-1364, BMG Labtech, Ortenberg, Germany) was utilised 
to measure fluorescence intensity of the respective probes (see below) in the abovementioned time- and 
concentration-response investigations. This commenced with the creation of the HIV-1-model, in other 
words, determining the ideal AEC exposure-time to HIV-1-proteins, as well as determining which of the 
three HIV-1-protein mediums (25ng/ml, 50ng/ml or 100ng/ml) resulted in an optimal HIV-1-environment. 
Once the HIV-1-model was created, the ART concentration-response investigations were performed 
within the optimised HIV-1-microenvironment.  
2.4.1 Materials 
 Clear base, black-frame 24-well Vision Plates™: Supplied by 4titude, Surrey, UK and supplied 
locally by Separations. 
 Serum free endothelial cell growth medium (EGM-2): Supplemented as described in 1.1, but 
without FBS.  
 Propidium iodide solution (1.0 mg/ml in water): Supplied by Sigma-Aldrich, St. Louis, Missouri, 
USA. 
 4,5-Diaminofluorescein diacetate (DAF-2 DA) (1mg): Supplied by Calbiochem®, EMD Millipore 
Corp., Billerica, MA, USA and distributed locally by Merck. 
 Diethylamine NONOate diethylammonium salt (DEA/NO) (D5431-50MG): Supplied by Sigma-
Aldrich, St. Louis, Missouri, USA. 
 Dihydrorhodamine-1, 2, 3 (DHR-123): Supplied by Sigma-Aldrich (St Louis, Mo, USA). 
 Peroxynitrite (Cat# 516620): Supplied by Calbiochem®, EMD Chemicals, Inc. San Diego, CA 
92121, and distributed locally by Merck. 
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2.4.2 Methods 
Cell Culture 
Aortic endothelial cells were cultured as described in 1 above and finally passaged to 24-well plates. A P1 
parent cell line yielded nine 24-well plates in total, a P2 parent cell line eight 24-well plates and a P3 
parent cell line five 24-well plates. View Appendix D for a visual representation.  
HIV-1-protein medium time- and concentration-response investigation protocol 
Once the cells in the 24-well plates reached ±80% semi-confluence, usually on day two after seeding the 
wells, they were serum starved for 24 hours. The 80% semi-confluence cut-off point was used in the case 
of the 24-well plates as a precaution against over-confluence at the time of analysis. Over-confluence can 
result in cell death and, due to the diminutive size of the wells (diameter: 14.5 mm) together with the 48 
hour period between serum starvation and analysis, this was a possibility that had to be avoided. Serum 
starvation was employed to induce cell cycle synchronization, enhancing the otherwise healthy cells‟ 
responses to the various treatments (Gerber et al., 1998; Russell and Hamilton, 2014). This entailed 
aspirating the FBS containing endothelial cell growth medium (EGM-2) and replacing it with serum free 
EGM-2, containing no FBS. After 24 hours, the serum free medium was aspirated and replaced with the 
various treatment and control mediums. Each 24-well plate was assigned three positive control wells, 
twelve treatment wells and nine vehicle control wells. The treatment wells were divided into three groups 
of four wells each, each for a different treatment concentration. Similarly, the vehicle control wells were 
divided into three groups of three wells each, each group to control for one of the three different treatment 
concentrations. The positive control wells were included to test the effectiveness of the various 
fluorescent probes and were given the normal EGM-2 (Figure 2.3). After 24 hours, the various media 
were aspirated and the plate reader assays conducted. The 48 hour treatment investigations entailed 
replacing the various media after 24 hours and exposing the AECs to these media for another 24 hours 
equalling a total of 48 hours before the various plate reader assays were conducted (Figure 2.4).  
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Figure 2.3: Well assignment for HIV-1-protein medium time- and concentration-response 
investigations. +: positive control; HIV1: HIV-medium 1 (25 ng/ml); HIV2: HIV-medium 2 (50 ng/ml); 
HIV3: HIV-medium 3 (100 ng/ml); VC1: vehicle control for HIV-medium 1; VC2: vehicle control for HIV-
medium 2; VC3: vehicle control for HIV-medium 3. 
 
 
Figure 2.4: Treatment Protocols 
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Antiretroviral drug treatment concentration-response investigation protocol 
After the development of the HIV-1-model, which stipulated that AECs be incubated in HIV-medium 3 
(100ng/ml) for 24 hours, the antiretroviral drug treatment concentration-response investigations were 
carried out. As with the HIV-1-protein medium time- and concentration-response investigations, AECs 
were serum starved for 24 hours upon reaching ±80% semi-confluence. Thereafter, as described above, 
the serum free medium was aspirated and replaced with the various treatment and control media as well 
as normal endothelial cell growth medium for the positive control wells (Figure 2.5). The cells were left to 
incubate for 24 hours, after which the plate reader assays were carried out (Figure 2.4). This process 
was repeated for the NRTI/NNRTI treatment and for the PI treatment. The antiretroviral drug media were 
only subjected to concentration-response investigations, as the findings from the HIV-1-model time-
response investigations suggested that a 24 hour treatment period was optimal. 
 
Figure 2.5: Well assignment for antiretroviral drug treatment (NRTI/NNRTI and PI) concentration-
response investigations. +: positive control; ART1: half-dose NRTI/NNRTI or PI treatment in HIV-
medium 3; ART2: single-dose NRTI/NNRTI or PI treatment in HIV-medium 3; ART3: double-dose 
NRTI/NNRTI or PI treatment in HIV-medium 3; VC1: vehicle control  for vehicles used in half-dose ART 
treatment and HIV-medium 3; VC2: vehicle control  for vehicles used in single-dose ART treatment and 
HIV-medium 3; VC3: vehicle control  for vehicles used in double-dose ART treatment and HIV-medium 3.  
 
Propidium Iodide Cell Viability Assay 
After the 24 or 48 hour treatment period the various treatment, control and positive control media were 
aspirated and the cells washed with PBS. Hereafter, the cells were treated with a Propidium Iodide (Prop. 
I) probe at a concentration of 5 μM. Prop. I is a large molecule that acts as a DNA stain, which, due to its 
size, is only able to enter cells once their membrane integrity has been compromised – as is the case with 
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necrosis (Riccardi and Nicoletti, 2006). Prop. I fluorescence is thus used as a measure for cell viability. 
For all the wells except the three positive control wells, the Prop. I was diluted in PBS, for the three 
positive control wells it was diluted in distilled water. PBS is isotonic to the cytosol, while distilled water is 
not. When distilled water is added to the cells, it results in water molecules diffusing across the semi-
permeable cell membrane from an area of high osmotic potential (the distilled water) to an area of low 
osmotic potential (the cytosol) eventually causing the cells to burst, thus exposing the DNA to the Prop. I 
for staining and resulting in a strong fluorescent signal. After adding the probe, the cells were incubated 
for 15 minutes and then taken to the plate reader for analysis (Figure 2.6). An excitation wavelength of 
544 nm was used and 640 nm for emission. For a more detailed description of the protocol view Appendix 
E. 
 
Figure 2.6: Propidium Iodide Cell Viability Assay. 
 
DAF-2/DA Nitric Oxide Detection Assay 
As described above, the various treatment media were removed and the cells washed with PBS, after 
which they were treated with the DAF-2/DA fluorescent probe diluted in PBS for a final concentration of 
10 μM. DAF-2/DA measures intracellular nitric oxide production. This molecule is able to pass through the 
plasma membrane and enter the cell, where it is hydrolysed to form DAF-2. DAF-2 cannot cross the 
plasma membrane and thus remains inside the cell where it reacts with NO to form fluorescent DAF-2 T 
(Kojima et al., 1998). Cells were incubated with DAF-2/DA for 90 minutes before 100 μM of the positive 
control, DEA/NO, which acts as a nitric oxide donor, was added to each of the three positive control wells. 
The cells were incubated for another 30 minutes where after the probe was aspirated and replaced with 
PBS and the cells were taken to the plate reader for analysis (Figure 2.7). The excitation wavelength 
used was 485 nm and emission 520 nm. For a more detailed description of the protocol view Appendix E. 
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Figure 2.7: DAF-2/DA NO Detection Assay. 
 
DHR-123 Nitrosative Stress Assay 
As with the previous assay protocols, treatment and control media were aspirated and the cells washed 
with PBS. Subsequently they were treated with DHR-123 diluted in PBS with a final concentration of 2 
μM. DHR-123 is an indicator of reactive nitrogen species (RNS), including peroxynitrite. It is able to 
penetrate the cell and once it reacts with peroxynitrite, DHR-123 is oxidised to rhodamine-123 which is 
highly fluorescent (Tarpey and Fridovich, 2001). Cells were incubated with DHR-123 for one hour, after 
which 100 μM of peroxynitrite was added to each of the three positive control wells. Cells were incubated 
for an additional 2 hours before being taken to the plate reader for analysis (Figure 2.8). The excitation 
wavelength used for the DHR-123 assay was 485 nm and the emission wavelength 520 nm. Refer to 
Appendix E for a more detailed description of the protocol. 
 
Figure 2.8: DHR-123 Nitrosative Stress Assay. 
 
2.5. WESTERN BLOT ANALYSES 
2.5.1 Materials 
 Criterion™ TGX Stain-Free™ (4-20%) 26-well Precast Gels: Supplied by Bio-Rad Laboratories, 
Inc. (Hercules, CA, USA). 
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 PageRuler™ Prestained Protein Ladder: Supplied by Thermo Scientific (Lithuania, EU) 
 Immobilon®-P Transfer Membrane (filter type: PVDF; pore size: 0.45μm): Supplied by Merck 
Millipore Ltd. (Tullagreen, Carrigtwohill, Co. Cork, Ireland). 
 Primary antibodies supplied by Cell Signaling Technologies (Beverly, MA, USA) and distributed 
locally by Anatech: 
o Total eNOS Rabbit (9572S; Lot 3) 
o Phospho eNOS (S1177) Rabbit (9571S; Lot 14) 
o Total PKB (Akt) Rabbit (9272S; Lot 27) 
o Phospho PKB (Akt) (S473) (D9E) XP(R) Rabbit (4060S; Lot 23) 
o IκBα Rabbit (9242S; Lot 10) 
o Cleaved PARP (D214) (Rat Specific) Rabbit (9545S; Lot 2) 
o Cleaved Caspase-3 (D175) Rabbit (9661S; Lot 45) 
 Primary antibodies supplied by Santa Cruz Biotechnologies (Santa Cruz, CA, USA) and 
distributed locally by Whitehead Scientific: 
o Nitrotyrosine (PNK) Rabbit Polyclonal IgG (sc-55256; Lot #D1112) 
o p22-phox (FL-195) Rabbit Polyclonal IgG (sc-20781; Lot #F1512)  
 Primary SingalBoost™ Immunoreaction Enhancer: Supplied by Millipore (Billerica, MA, USA) and 
distributed locally by Merck. 
 Anti-rabbit immunoglobulin G, HRP-linked secondary antibody: Supplied by Cell Signaling 
Technologies (Beverly, MA, USA) and distributed locally by Anatech. 
 Clarity™ enhanced chemiluminescence (ECL) detection reagent: Supplied by Bio-Rad (Hercules, 
CA, USA) and distributed locally by Lasec. 
 All other chemicals and buffer reagents were supplied by Sigma-Aldrich (St Louis, Mo, USA) and 
Merck (Darmstadt, Germany). 
2.5.2 Methods 
Cell Culture 
AECs were cultured as described previously and finally passaged to six 100 mm petri dishes (Figure 2.9). 
A final total of three P1 parent cell lines were used for western blotting purposes, to ensure a final sample 
size made up of biological replicates derived from three different parent cell lines based on experiments 
performed on separate occasions. 
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Figure 2.9: Passaging a P1 cell-line to six 100mm petri dishes. 
 
Treatment Protocol 
Upon reaching confluence, cells were serum starved following the same procedure as described for the 
plate reader assays. For western blotting purposes, cells were allowed to grow to full confluence as a 
high protein yield was essential. One fully confluent 100 mm petri dish yielded sufficient protein for one 
lysate. Hereafter, cells were treated for 24 hours before being lysed for protein extraction. View the 
various treatment groups in Table 2.1.  
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Table 2.1: Western Blotting Treatment Groups. 
1. Combined Vehicle 
Control (CVC) 
AECs incubated in combined vehicle control medium for 24 hours 
(see a more detailed description of this medium in the following 
section). 
2. HIV-Protein Treatment 
Group  
AECs incubated in HIV-medium 3 (100 ng/ml of Tat, Gp160 and Nef) 
for 24 hours. 
3. NRTI/NNRTI Treatment 
Group 
AECs incubated in endothelial growth medium containing a single-
dose of NRTI/NNRTI treatment (5.6 nM EFV, 500 nM TDF and 1.3 
μM FTC) for 24 hours. 
4. PI Treatment Group 
AECs incubated in endothelial growth medium containing a single-
dose of PI treatment (10 μM LPV and 2 μM RTV) for 24 hours. 
5. HIV-Protein + 
NRTI/NNRTI Treatment 
Group 
AECs incubated in HIV-medium 3 (100 ng/ml of Tat, Gp160 and Nef) 
containing a single dose of NRTI/NNRTI treatment (5.6 nM EFV, 500 
nM TDF and 1.3 μM FTC) for 24 hours. 
6. HIV-Protein + PI 
Treatment Group 
AECs incubated in HIV-medium 3 (100 ng/ml of Tat, Gp160 and Nef) 
containing a single dose of PI treatment (10 μM LPV and 2 μM RTV) 
for 24 hours. 
  
 
Combined Vehicle Control (CVC) 
To avoid having multiple vehicle controls, each controlling for the different vehicles and concentrations in 
each of the treatment groups, a combined vehicle control medium was created. Prior to use, this 
combined vehicle control medium was also subject to plate reader analyses (Prop. I and DAF-2/DA) to 
determine whether this cocktail had any seriously detrimental effects on AECs, and it was ascertained 
that the combined vehicle control had no effects on these parameters. Furthermore, western blotting for 
eNOS and PKB/Akt was performed to determine whether the combined vehicle control still allowed for the 
detection of these proteins, which it did. The combined vehicle control medium contained 1.6 % PBS, 
controlling for the PBS vehicle used for the HIV-1-proteins and NRTI/NNRTI drugs, and 0.2 % DMSO 
controlling for the DMSO vehicle of the PI drugs. The additional NRTI/NNRTI drug vehicles of MeOH and 
dH₂O constituted such insignificant amounts (0.000027 % MeOH and 0.000143 % dH₂O) that they would 
be impossible to pipette and thus deemed negligible. Moreover, vehicles not present in a certain 
treatment group had to be added to that group (the same concentration as in the groups containing it) to 
ensure that that all the vehicles were controlled for in all six groups (Table 2.2).  
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Table 2.2: Controlling for Vehicles. 
 
Original vehicle 
concentration  
Concentration of 
vehicle added 
Final vehicle 
concentration 
1. Combined Vehicle 
Control (CVC) 
- 
0.2 % DMSO 
1.6 % PBS 
0.2 % DMSO 
1.6 % PBS 
2. HIV-Protein Treatment 
Group  
1.3 % PBS 
0.2 % DMSO 
0.3 % PBS 
0.2 % DMSO 
1.6 % PBS 
3. NRTI/NNRTI Treatment 
Group 
0.3 % PBS 
0.2 % DMSO 
1.3 % PBS 
0.2 % DMSO 
1.6 % PBS 
4. PI Treatment Group 0.2 % DMSO 1.6 % PBS 
0.2 % DMSO 
1.6 % PBS 
5. HIV-Protein + 
NRTI/NNRTI Treatment 
Group 
1.6 % PBS 0.2 % DMSO 
0.2 % DMSO 
1.6 % PBS 
6. HIV-Protein + PI 
Treatment Group 
0.2 % DMSO 
1.3 % PBS 
0.3 % PBS 
0.2 % DMSO 
1.6 % PBS 
 
 
Protein Extraction 
After the 24 hour treatment period, the treatment and control media were aspirated, the cells washed and 
8 ml of PBS added to each petri dish. The cells were removed from the bottom of the petri dish using a 
rubber cell-scraper. The cell-containing PBS was transferred to marked 15 ml conical tubes and 
centrifuged for 3 minutes at 1000 rpm at 4°C, where after most of the PBS was aspirated and the pellets 
transferred to marked Eppendorf Tubes®. The centrifugation was subsequently repeated in order to 
aspirate any remaining PBS. Zirconium oxide beads (0.5 mm), at an amount roughly the size of the pellet, 
were added to each Eppendorf Tube® as well as 800 μl of lysis buffer (Table 2.3). The cells were 
homogenized using a Bullet Blender™ (Next Advance, Inc., NY, USA) and the samples left on ice for 20 
minutes after which they were centrifuged for 20 minutes at 15000 rpm at 4 °C. Finally, the supernatant 
was removed and placed in new, marked Eppendorf Tubes®, before being frozen away at -80 °C for 
future use.  
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
49 
 
Table 2.3: Lysis Buffer 
Reagent 
Final 
concentration 
in buffer 
Amount of 
10X stock 
for 10ml 
Action 
Tris-HCl (pH 7.5) 
EGTA [ethylene glycol 
tetraacetic acid] 
20.0 mM 
1.0 ml 
Buffer 
1.0 mM Chelating agent 
EDTA 
[ethylenediaminetetraacetic 
acid] 
1.0 mM 0.1 ml 
Chelating agent (metalloprotease 
inhibitor)  
NaCl 150 mM 1.5 ml Salt 
Β-glycerophosphate 
1.0 mM 0.002 g 
Serine/Threonine phosphatase 
inhibitor 
Tetra-sodium pyrophosphate 
2.5 mM 0.01 g 
Serine/Threonine phosphatase 
inhibitor 
Sodium dodecyl sulphate (SDS) 0.1 % 0.1 ml Detergent 
Na₃VO₄ (0.18g/10ml dH₂O) 
1.0 mM 0.1 ml 
Tyrosine and alkaline 
phosphatase inhibitor 
Triton-X100 (10%) 1.0 % 1 ml Detergent 
Protease Inhibitor Cocktail 
1.0 % 0.01 ml 
 
1) AEBSF [4-(2-Aminoethyl) 
benzenesulfonyl fluoride 
hydrochloride] 
Serine protease inhibitor 
2) Aprotinin Serine protease inhibitor 
3) Bestatin hydrochloride Aminopeptidase inhibitor 
4) E-64 [N-(trans-
Epoxysuccinyl)-L-leucine 4-
guanidinobutylamide] 
cysteine protease inhibitor 
5) Leupeptin hemisulfate salt Serine and cysteine protease 
inhibitor 
6) Pepstatin A acid protease inhibitor 
NaF 
50 nM 0.0213 g 
Serine/Threonine and acidic 
phosphatase inhibitor 
PMSF [Phenylmethylsulfonyl 
fluoride] 
50 μg/ml 0.03 ml Serine protease inhibitor 
Fill up to 10 ml with distilled water (add 6.16 ml) 
 
 
Lysate Preparation 
Once the supernatants of all the western blot P1 parent cell lines had been collected, they were removed 
from -80 °C storage, thawed and subjected to the Bradford assay (Bradford, 1976) for protein content 
determination. Lysates were prepared accordingly, containing 2X Laemmli buffer (Table 2.4), lysis buffer 
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and supernatant ensuring a final protein content of 8 μg per 18 μl of lysate for all samples. Lysates were 
boiled for 5 minutes and frozen away at -80 °C for later use. View Appendix F for more details on the 
Bradford assay calculations.  
Table 2.4: 2X Laemmli Buffer (Laemmli, 1970). 
Reagent Concentration 
SDS 4 % 
Glycerol 20 % 
2-Mercaptoethanol 10 % 
Bromophenol blue 0.004 % 
Tris HCl 0.125 M 
 
 
Separation and Transfer of Proteins  
Lysates were from -80°C storage, thawed, boiled for 3 minutes and centrifuged for 5 minutes at 15000 
rpm before being loaded in 26-well Criterion™ TGX Stain-Free™ gels. A PageRuler™ ladder was loaded 
into the first and last well of each gel and 18 μl of lysate was loaded per sample (Figure 2.10). Proteins 
were separated at 200 V and 200 mA for 50 minutes to separate the proteins according to size. Once the 
running process was completed, the gels were activated using the Chemidoc™ MP Imager System with 
Image Lab™- 5 software (Bio-Rad, CA, USA), to ascertain whether protein loading for the different 
samples was equal. Hereafter, the separated proteins on the gels were transferred to Immobilon®-P 
transfer membranes using the Trans-Blot® Turbo™ Transfer System (Bio-Rad, CA, USA). This was done 
on ice at 200 V and 200 mA for 90 minutes. Subsequently, the membranes were visualised on the 
Chemidoc™ to ensure that all proteins had transferred correctly, and so images could later be used for 
normalisation. Proteins on the membranes were fixed by submerging in MeOH for 5 minutes. 
 
 
 
Figure 2.10: Lysate loading. Within each treatment group of three wells each, the first originated from 
P1 parent cell line 1, the second from P1 parent cell line 2 and the third from P1 parent cell line 3, hence 
providing three distinct biological replicates. 
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Immunodetection of Proteins 
Membranes were blocked for non-specific binding for 2 hours using a 10 % Tris-buffered saline, 0.1 % 
Tween solution (TBS-Tween) with 5 % fat-free milk. After blocking, the membranes were washed using 
TBS-Tween (3 x 5minute cycles), cut and the various sections each incubated overnight at 4 °C in a 
primary antibody (Table 2.5). Due to the relatively low protein content of the lysates, all primary 
antibodies were diluted with SignalBoost™. The following morning, the membranes were washed and 
incubated for 1 hour at room temperature in an anti-rabbit immunoglobulin G, horseradish peroxidase 
(HRP) conjugated secondary antibody optimised for the various proteins (Table 2.5). Hereafter, 
membranes were washed and incubated in Clarity™ ECL for 5 minutes before being exposed using the 
Chemidoc™. Image Lab™- 5 software was used for normalisation, a process which involved correcting 
for any differences in protein loading evident from the initial membrane visualisation step. The membrane 
sections were then stripped of their original antibody and re-incubated in a different one. Stripping 
entailed first washing membranes in dH₂O (2 x 5 minute cycles), followed by a 5 minute wash in 0.2 M 
NaOH and finally two more dH₂O wash cycles. Hereafter the immunodetection process, commencing with 
the blocking of the membranes, was repeated. 
 
Table 2.5: Primary and Secondary Antibody Dilutions 
Protein Weight Function 
Primary Antibody 
Dilution 
Secondary 
Antibody Dilution 
Total eNOS  
140 kDa Nitric Oxide synthesis 
1:1000 
(5 μl in 5 ml 
Primary 
SignalBoost™) 
1:4000 
(5 μl in 20 ml TBS-
Tween) 
Phospho eNOS  
Total PKB (Akt)  
60 kDa 
Upstream activation of 
eNOS Phospho PKB (Akt) 
IκBα 39 kDa Marker of inflammation 
Cleaved-PARP 89kDa Marker of apoptosis 
Cleaved Caspase-3  
17/19 
kDa 
Marker of apoptosis 
Nitrotyrosine  90 kDa 
Marker of nitrosative 
stress 
1:200 
(25 μl in 5 ml 
Primary 
SignalBoost™) 
p22-phox  22 kDa 
Marker of oxidative 
stress 
1:4000 5 % milk 
(5 μl in 20 ml TBS-
Tween 
supplemented with 
5 % milk) 
 
 
Protein Normalisation 
All raw values (pixel counts) were normalised using Image Lab™- 5 software (Bio-Rad, CA, USA) to 
quantify protein expression and account for protein loading. Total protein normalisation (TPN) was 
employed, where western blot data are analysed using the total protein in samples, thus making the use 
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of house-keeping proteins (HKP) unnecessary. The TPN technique is faster, more accurate and more 
reliable than HKP-based normalisation (Gürtler et al., 2013). The best way to measure total protein in a 
blot or gel is via stain-free technology which relies on a UV-mediated reaction between a trihalo 
compound present in the stain-free acrylamide gels and tryptophan residues on proteins, which produces 
fluorescence. This allows for the reliable detection of any tryptophan-containing protein, including the 
majority of actively researched proteins (MacDonald et al., 2008). To view the images of the Immobilon®-
P transfer membranes (with proteins transferred from the Criterion™ TGX Stain-Free™ (4-20%) 26-well 
Precast Gels) used for this TPN process, refer to Appendix I. 
 
2.6. STATISTICAL ANALYSIS 
All data were analysed using GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA). 
Statistical significance was set at p <0.05. 
2.6.1 Plate Reader Assays 
One parent cell line was regarded as a single n-value and thus all experiments performed on cells sub-
cultured from a single parent cell line were considered to be technical replicates (Table 2.6). All technical 
replicate values were therefore averaged to obtain a single value (n=1) per treatment group per parent 
cell line for statistical analysis. A final n=4 was used for all experimental groups in the plate-reader 
analyses. Furthermore, all raw fluorescence values were converted to and expressed as a percentage of 
the vehicle control. Student‟s t-tests were employed when comparing two groups and for more than two 
groups, one-way analysis of variance (ANOVA) with Tukey‟s multiple comparisons post hoc tests were 
utilised.  
Table 2.6: Example of technical replicates versus n-values (biological replicates). One parent cell 
line yields multiple technical replicates, but only constitutes n=1 per treatment group. HIV1: HIV-medium 
1; HIV2: HIV-medium 2; HIV3: HIV-medium 3. 
HIV-1-Protein Medium Treatment  
Parent Cell Line Propidium Iodide DAF-2/DA DHR-123 
P3 
   
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
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HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
Sub-Total Technical 
Repeats 
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
4 4 4 8 8 8 8 8 8 
Sub-Total n-value 1 1 1 1 1 1 1 1 1 
P2 
   
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
  
 
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
   
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
4 tech 
reps 
Sub-Total Technical 
Repeats 
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
12 12 12 12 12 12 8 8 8 
Sub-Total n-value 1 1 1 1 1 1 1 1 1 
Total Technical 
Repeats 
HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 HIV1 HIV2 HIV3 
16 16 16 20 20 20 16 16 16 
Total n-value 2 2 2 2 2 2 2 2 2 
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2.6.2 Western Blot Analyses 
Initially, the intention was to have a sample size of n=4 /group for the western blot measurements – as 
with the plate reader assays. Knowing that AECs often do not yield sufficient protein, five P1 cell lines 
were cultured for western blotting purposes. However, only three of these P1 parent cell lines yielded a 
sufficient amount of protein. This resulted in a final n=3 per treatment group. Normalised raw values were 
converted to fractions of the combined vehicle control. Ordinary one-way ANOVAs with Tukey‟s multiple 
comparisons post hoc tests were employed.  
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CHAPTER 3: RESULTS 
 
The results are presented chronologically, commencing with the plate reader analyses utilised in the 
development of the HIV-1-protein model (time- and concentration-response investigations) (Section 3.1), 
followed by the antiretroviral drug concentration-response investigations within this optimised HIV-1-
protein environment (Section 3.2). Finally, the western blot protein expression and phosphorylation data 
are described in Section 3.4. All data are presented graphically. For the exact mean ± SEM values of all 
the experiments, please view Tables 3.2 – 3.26 in Appendix G. 
 
3.1. HIV-1-PROTEIN MEDIUM TIME- AND CONCENTRATION-RESPONSE 
INVESTIGATIONS 
After exposure to serum starvation for 24 hours, AECs were treated with three different concentrations 
(25 ng/ml, 50 ng/ml and 100 ng/ml) of a HIV-protein cocktail consisting of Tat, Nef and Gp160 for a 
duration of either 24 or 48 hours. This was compared with vehicle controls containing matching 
concentrations of the PBS vehicle used to dissolve the HIV-1-proteins. Subsequently the effects on cell 
viability, nitric oxide production and nitrosative stress were assessed using a plate reader. For all groups 
n=4. Results regarding the functionality of the various fluorescent probes can be viewed in Appendix H. 
For a more detailed description of the methods involved, refer to Chapter 2. 
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3.1.1 24-hour Exposure 
Propidium Iodide Cell Viability Assay 
No significant effects on cell viability were detected following the treatment of AECs with three different 
concentrations of HIV-1 proteins for 24 hours. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons test was performed.  
   
Figure 3.1: Cell viability after 24 hours of HIV-1-protien exposure. VC 1: vehicle control for 25 ng/ml 
HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-protein cocktail; VC 3: vehicle control for 100 
ng/ml HIV-protein cocktail. n=4/group. Note that all raw fluorescence values were converted to and 
expressed as a percentage of the vehicle controls, thus 100% fluorescence does not indicate 100% non-
viable cells for a treatment group, but merely the proportion of non-viable cells in that treatment group 
compared to the vehicle control. 
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DAF-2/DA Nitric Oxide Production Assay 
Treatment of AECs with 100 ng/ml of HIV-1 proteins for 24 hours resulted in a significant reduction in 
Nitric Oxide (NO) production compared to 25 ng/ml of HIV-proteins (72.05 ± 8.37% vs. 100.8 ± 5.25%; 
p=0.02) and Vehicle Control 3 (72.05 ± 8.37% vs. 100 ± 1.55%; p=0.02).  An ordinary one-way ANOVA 
with Tukey‟s multiple comparisons test was performed. 
 
Figure 3.2: NO production after 24 hours of HIV-1-protein exposure. VC 1: vehicle control for 25 
ng/ml HIV-protein cocktail, VC 2: vehicle control for 50 ng/ml HIV-protein cocktail; VC 3: vehicle control for 
100 ng/ml HIV-protein cocktail. *: p<0.05. n=4/group. Note that all raw fluorescence values were 
converted to and expressed as a percentage of the vehicle controls. 
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DHR-123 Nitrosative Stress Assay 
No significant effects on nitrosative stress were detected following the treatment of AECs with three 
different concentrations of HIV-1 proteins for 24 hours. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons test was performed. 
 
Figure 3.3: Nitrosative stress after 24 hours of HIV-1-protein exposure. VC 1: vehicle control for 25 
ng/ml HIV-protein cocktail, VC 2: vehicle control for 50 ng/ml HIV-protein cocktail; VC 3: vehicle control for 
100 ng/ml HIV-protein cocktail. n=4/group. Note that all raw fluorescence values were converted to and 
expressed as a percentage of the vehicle controls. 
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3.1.2 48-hour Exposure 
Propidium Iodide Cell Viability Assay 
Treatment of AECs with 100 ng/ml of HIV-1 proteins for 48 hours resulted in a significant increase in non-
viable cells compared to the 25 ng/ml group (118.2 ± 7.69% vs. 98.37 ± 4.61%; p=0.04), however, there 
was no significance compared to the vehicle control. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons test was performed. 
 
Figure 3.4: Cell viability after 48 hours of HIV-1-protien exposure. VC 1: vehicle control for 25 ng/ml 
HIV-protein cocktail, VC 2: vehicle control for 50 ng/ml HIV-protein cocktail; VC 3: vehicle control for 100 
ng/ml HIV-protein cocktail. *: p<0.05. n=4/group. Note that all raw fluorescence values were converted to 
and expressed as a percentage of the vehicle controls, thus 100% fluorescence does not indicate 100% 
non-viable cells for a treatment group, but merely the proportion of non-viable cells in that treatment 
group compared to the vehicle control.  
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
60 
 
DAF-2/DA Nitric Oxide Production Assay 
No significant differences in NO production were detected following the treatment of AECs with three 
different concentrations of HIV-1 proteins for 48 hours. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons test was performed. 
 
Figure 3.5: NO production after 48 hours of HIV-1-protein exposure. VC 1: vehicle control for 25 
ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-protein cocktail; VC 3: vehicle control for 
100 ng/ml HIV-protein cocktail. n=4/group. Note that all raw fluorescence values were converted to and 
expressed as a percentage of the vehicle controls. 
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DHR-123 Nitrosative Stress Assay 
No significant effects on nitrosative stress were detected following the treatment of AECs with three 
different concentrations of HIV-1 proteins for 48 hours. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons test was performed. 
 
Figure 3.6: Nitrosative stress after 48 hours of HIV-1-protein exposure.  VC 1: vehicle control for 25 
ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-protein cocktail; VC 3: vehicle control for 
100 ng/ml HIV-protein cocktail. n=4/group. Note that all raw fluorescence values were converted to and 
expressed as a percentage of the vehicle controls. 
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3.1.3 HIV-1-Model 
Based on the above results, an HIV-1-model was decided upon for use in the next set of investigations. 
Exposing AECs to 100 ng/ml of HIV-1-proteins for 24 hours elicited a cellular response (decreased NO 
production – a marker of impaired endothelial cell function) without causing a significant increase in non-
viable cells. Thus, the HIV-1-model constituted treating serum starved AECs with 100 ng/ml of a Tat, Nef 
and Gp160 cocktail or 24 hours. 
 
3.2. ANTIRETROVIRAL DRUG TREATMENT CONCENTRATION-RESPONSE 
INVESTIGATIONS 
After the HIV-1-model was developed, the antiretroviral drug treatment was subject to concentration-
response investigations within the previously established HIV-1 environment (financial constraints and the 
limited space of the 24-well plates meant that the drugs could not be tested individually). The effects of 
NRTI/NNRTIs and PIs with HIV-1-proteins on cell viability, NO production and nitrosative stress were 
determined using a plate reader. After exposure to serum starvation for 24 hours, AECs were treated with 
three different concentrations of antiretroviral drugs plus 100 ng/ml of Tat, Nef and Gp160 for 24 hours. 
For all groups n=4. Results regarding the functionality of the various fluorescent probes can be viewed in 
Appendix H. For a more detailed description of the methods involved, refer to Chapter 2. 
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3.2.1 NRTI/NNRTI Treatment 
The three different concentrations of NRTI/NNRTI treatment included single dose treatment (5.6 nM EFV, 
500 nM TDF, 1.3 μM FTC), half dose treatment (2.8 nM EFV, 250 nM TDF, 0.65 μM FTC) and double 
dose treatment (11.2 nM EFV, 1 μM TDF, 2.6 μM FTC). These drugs were all administered in conjunction 
with the 100 ng/ml HIV-1-protein cocktail. This was compared with vehicle controls containing matching 
concentrations of the vehicles used to dissolve the HIV-1-proteins (PBS) as well as the NRTI/NNRTI 
drugs (PBS, MeOH, dH₂O). The vehicle controls did not contain HIV-1- proteins. 
Propidium Iodide Cell Viability Assay 
Treatment with double dose NRTI/NNRTI resulted in a significant increase in non-viable cells compared 
to half dose (104.7 ± 2.7% vs. 95.56 ± 0.63; p=0.02) and single dose (104.7 ± 2.7 vs. 96.17 ± 3.4; p=0.04) 
treatment, however, not compared to the vehicle control. An ordinary one-way ANOVA with Tukey‟s 
multiple comparisons test was performed. 
 
Figure 3.7: Cell viability after 24 hours of NRTI/NNRTI treatment within an HIV-1 environment. VC 
1: vehicle control for half dose NRTI/NNRTI treatment, VC 2: vehicle control for single dose NRTI/NNRTI 
treatment; VC 3: vehicle control for double dose NRTI/NNRTI treatment. *: p<0.05. n=4/group. Note that 
all raw fluorescence values were converted to and expressed as a percentage of the vehicle controls, 
thus 100% fluorescence does not indicate 100% non-viable cells for a treatment group, but merely the 
proportion of non-viable cells in that treatment group compared to the vehicle control. 
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DAF-2/DA Nitric Oxide Production Assay 
No significant effects on NO production were detected following the treatment of AECs with 
NRTI/NNRTIs. An ordinary one-way ANOVA with Tukey‟s multiple comparisons test was performed. 
 
Figure 3.8: NO levels after 24 hours of NRTI/NNRTI treatment within an HIV-1 environment VC 1: 
vehicle control for half dose NRTI/NNRTI treatment, VC 2: vehicle control for single dose NRTI/NNRTI 
treatment; VC 3: vehicle control for double dose NRTI/NNRTI treatment. n=4/group. Note that all raw 
fluorescence values were converted to and expressed as a percentage of the vehicle controls. 
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DHR-123 Nitrosative Stress Assay 
All three NRTI/NNRTI dosages resulted in significant reductions in nitrosative stress in AECs [Half Dose 
vs. Vehicle Control 1 (86.57 ± 3.52% vs. 100 ± 0.28% p=0.01); Single Dose vs. Vehicle Control 2 (83.19% 
± 3.5 vs. 100 ± 0.22%; p=0.002); Double Dose vs. Vehicle Control 3 (86.14 ± 3.29% vs. 100 ± 0.48%; 
p=0.009)]. An ordinary one-way ANOVA with Tukey‟s multiple comparisons test was performed. 
 
Figure 3.9: Nitrosative stress after 24 hours of NRTI/NNRTI treatment within an HIV-1 environment. 
VC 1: vehicle control for half dose NRTI/NNRTI treatment, VC 2: vehicle control for single dose 
NRTI/NNRTI treatment; VC 3: vehicle control for double dose NRTI/NNRTI treatment. *: p<0.05; **: 
p<0.01. n=4/group. Note that all raw fluorescence values were converted to and expressed as a 
percentage of the vehicle controls. 
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3.2.2 PI Treatment 
The three different concentrations of PI treatment included a single dose (10 μM LPV, 2 μM RTV), half 
dose (5 μM LPV, 1 μM RTV) and double dose of PI drugs (20 μM LPV, 4 μM RTV). As with the 
NRTI/NNRTI groups, these drugs were administered in conjunction with 100 ng/ml of the HIV-1-protein 
cocktail. This was compared with vehicle controls containing matching concentrations of the vehicles 
used to dissolve the HIV-1-proteins (PBS) as well as the PI drugs (DMSO). The vehicle controls did not 
contain HIV-1-proteins. 
Propidium Iodide Cell Viability Assay 
Double dose PI treatment resulted in a significant increase in the non-viable cells compared to half dose 
(106.7 ± 6.14% vs. 94.26 ± 0.89%; p=0.03) and single dose (106.7 ± 6.14% vs. 94.33 ± 0.79; p=0.03) 
treatment, but not compared to the vehicle control. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons test was performed. 
 
 
Figure 3.10: Cell viability after 24 hours of PI treatment within an HIV-1 environment. VC 1: vehicle 
control for half dose PI treatment, VC 2: vehicle control for single dose PI treatment; VC 3: vehicle control 
for double dose PI treatment. *: p<0.05. n=4/group. Note that all raw fluorescence values were converted 
to and expressed as a percentage of the vehicle controls, thus 100% fluorescence does not indicate 
100% non-viable cells for a treatment group, but merely the proportion of non-viable cells in that 
treatment group compared to the vehicle control. 
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DAF-2/DA Nitric Oxide Production Assay 
Treatment with both single dose and double dose PI resulted in significant reductions in NO production 
[Single Dose vs. Half Dose (92.74 ± 1.4% vs. 100.2 ± 1.85% p=0.006); Double Dose vs. Half Dose (85 ± 
1.81% vs. 100.2 ± 1.85% p<0.001); Single Dose vs. Vehicle Control 2 (92.74 ± 1.4% vs. 100 ± 0.67%; 
p=0.008); Double Dose vs. Single Dose (85 ± 1.81% vs. 92.74 ± 1.4%; p=0.004); Double Dose vs. 
Vehicle Control 3 (85 ± 1.81% vs. 100 ± 0.56%; p<0.001)]. An ordinary one-way ANOVA with Tukey‟s 
multiple comparisons test was performed. 
 
Figure 3.11: NO levels after 24 hours of PI treatment within an HIV-1 environment. VC 1: vehicle 
control for half dose PI treatment, VC 2: vehicle control for single dose PI treatment; VC 3: vehicle control 
for double dose PI treatment. *: p<0.05; **: p<0.01; ***: p<0.001. n=4/group. Note that all raw 
fluorescence values were converted to and expressed as a percentage of the vehicle controls. 
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DHR-123 Nitrosative Stress Assay 
PI treatment had no significant effect on nitrosative stress levels for any of the treatment concentrations. 
An ordinary one-way ANOVA with Tukey‟s multiple comparisons test was performed. 
 
Figure 3.12: Nitrosative stress after 24 hours of PI treatment within an HIV-1 environment. VC 1: 
vehicle control for half dose PI treatment, VC 2: vehicle control for single dose PI treatment; VC 3: vehicle 
control for double dose PI treatment. n=4/group. Note that all raw fluorescence values were converted to 
and expressed as a percentage of the vehicle controls. 
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3.3. COMBINED VEHICLE CONTROL 
To avoid having multiple vehicle controls for western blotting, a combined vehicle control was created. 
This entailed combining all the vehicles used in the HIV-1-protein, NRTI/NNTRI and PI treatments which 
included PBS and DMSO. Before using this combined vehicle control cocktail, its effects on cell viability 
and NO production were assessed using a plate reader. Western blot analysis was used to probe for 
PKB/Akt.and eNOS to ensure that these key vascular signalling proteins could still be detected. After 
being serum starved for 24 hours, AECs either received normal growth medium (Control) or they were 
treated with the combined vehicle control (CVC) cocktail for 24 hours. A single cell line was used due to 
time and financial constraints; the n-values described below are thus only technical repeats. Results 
regarding the functionality of the various fluorescent probes can be viewed in Appendix H. For a more 
detailed description of the methods involved, refer to Chapter 2. 
3.3.1 Plate-reader Assays 
Propidium Iodide Cell Viability Assay 
The combined vehicle control had no effect on cell viability compared to the normal growth medium 
control. A Student‟s t-test was performed. 
 
 
Figure 3.13: Cell viability after 24 hours of CVC exposure. CVC: combined vehicle control. For Control 
n=3 and for CVC n=6. Note that all raw fluorescence values were converted to and expressed as a 
percentage of the control. 
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DAF-2/DA Nitric Oxide Production Assay 
The combined vehicle control had no effect on NO production compared to the normal growth medium 
control. A Student‟s t-test was performed. 
 
Figure 3.14: NO levels after 24 hours of CVC exposure. CVC: combined vehicle control. For Control 
n=3 and for CVC n=6. Note that all raw fluorescence values were converted to and expressed as a 
percentage of the control. 
 
3.3.2 Western Blotting 
Total eNOS 
Exposure to the CVC did not affect the expression of total eNOS in the AECs. 
 
Figure 3.15: eNOS expression after 24 hours of CVC exposure. For Control n=1 and for CVC 
n=2.CVC: Combined Vehicle Control. 
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Total PKB/Akt  
Total PKB/Akt was expressed in the AECs of both the control and CVC. 
 
Figure 3.16: PKB/Akt expression after 24 hours of CVC exposure. For Control n=1 and for CVC n=2. 
CVC: Combined Vehicle Control. 
 
3.4. VASCULAR SIGNALLING PROTEINS 
After the time- and concentration-response investigations were concluded, western blot analyses were 
performed to determine the expression and activation of various important vascular signalling proteins. 
View the various treatment groups in Table 3.1 below. For all groups an n=3 was performed, unless 
otherwise specified. For a more detailed description of the methods involved, refer to Chapter 2. 
Table 3.1: Western blotting treatment groups 
Name Treatment Controlling for Vehicles 
1. Combined Vehicle Control - 0.2% DMSO and 1.6% PBS 
2. HIV 100 ng/ml of Tat, Gp160 and Nef 0.2% DMSO and 0.3% PBS 
3. NRTI/NNRTI 
5.6 nM EFV, 500 nM TDF and 
1.3 μM FTC 
0.2% DMSO and 1.3% PBS 
4. PI 10 μM LPV and 2 μM RTV 1.6% PBS 
5. HIV + NRTI/NNRTI 
100 ng/ml of Tat, Gp160 and Nef 
+ 5.6 nM EFV, 500 nM TDF and 
1.3 μM FTC 
0.2% DMSO 
6. HIV + PI 
100 ng/ml of Tat, Gp160 and Nef 
+10 μM LPV and 2 μM RTV 
0.3% PBS 
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3.4.1 Nitric Oxide Synthesis 
eNOS  
Combined HIV-protein and PI treatment resulted in a significant reduction in eNOS expression in AECs 
compared to the combined vehicle control (0.28 ± 0.04 vs. 1 ± 0.21; p=0.01), HIV-protein only group (0.28 
± 0.04 vs. 1.17 ± 0.16; p=0.003) and PI group (0.28 ± 0.04 vs. 0.93 ± 0.1; p=0.03). None of the 
interventions had any effects on phosphorylated eNOS levels. Analyses included phosphorylated eNOS 
as well as phosphorylated / total eNOS ratios. Ordinary one-way ANOVAs with Tukey‟s multiple 
comparisons tests were performed. 
A 
 
B 
 
  
C 
 
Figure 3.17: eNOS expression and phos-
phorylation after 24 hours. CVC: Combined 
vehicle control; HIV: HIV-protein cocktail; 
NRTI/NNRTI: nucleoside analogue reverse 
transcriptase inhibitors/non-nucleoside reverse 
transcriptase inhibitors; PI: protease inhibitors.       
*: p<0.05; **: p<0.01. Arbitrary units: pixel counts 
depicted here as ratios relative to the CVC, which 
was expressed as 1. n=3/group. 
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PKB/Akt  
Significant reductions in PKB/Akt expression were observed in most treatment groups [HIV vs. CVC (0.84 
± 0.3 vs. 1 ± 0.03; p= 0.04); NRTI/NNRTI vs. CVC (0.79 ± 0.04 vs. 1 ± 0.03; p=0.008); PI vs. CVC (0.79 ± 
0.01 vs. 1 ± 0.03; p=0.008); HIV + NRTI/NNRTI vs. CVC (0.83 ± 0.05 vs. 1 ± 0.03; p=0.03); HIV + PI vs. 
CVC (0.68 ± 0.02 vs. 1 ± 0.03; p<0.001); HIV + PI vs. HIV (0.68 ± 0.02 vs. 0.84 ± 0.03; p=0.04)]. None of 
the interventions had any effects on phosphorylated PKB/Akt levels. Analyses included phosphorylated 
PKB as well as phosphorylated / total PKB/Akt ratios. Ordinary one-way ANOVAs with Tukey‟s multiple 
comparisons tests were performed. 
A 
 
B 
 
  
C 
 
Figure 3.18: PKB/Akt expression and phos-
phorylation after 24 hours. CVC: Combined 
vehicle control; HIV: HIV-protein cocktail; 
NRTI/NNRTI: nucleoside analogue reverse 
transcriptase inhibitors/non-nucleoside reverse 
transcriptase inhibitors; PI: protease inhibitors. *: 
p<0.05; **: p<0.01; ***: p<0.001. Arbitrary units: 
pixel counts depicted here as ratios relative to the 
CVC, which was expressed as 1. n=3/group. 
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3.4.2 Inflammation 
IκBα 
Combined HIV-protein and PI treatment resulted in a significant reduction in IκBα expression in AECs 
compared to the combined vehicle control (0.37 ± 0.03 vs. 1 ± 0.15; p<0.001), the HIV only treatment 
group (0.37 ± 0.03 vs. 0.93 ± 0.019; p=0.002) and the combined HIV and NRTI/NNRTI treatment group 
(0.37 ± 0.03 vs. 0.79 ± 0.05; p=0.02). An ordinary one-way ANOVA with Tukey‟s multiple comparisons 
test was performed. 
 
 
Figure 3.19: IκBα expression after 24 hours. CVC: Combined vehicle control; HIV: HIV-protein cocktail; 
NRTI/NNRTI: nucleoside analogue reverse transcriptase inhibitors/non-nucleoside reverse transcriptase 
inhibitors; PI: protease inhibitors. *: p<0.05; **: p<0.01; ***: p<0.001. Arbitrary units: pixel counts depicted 
here as ratios relative to the CVC, which was expressed as 1. n=3/group. 
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3.4.3 Apoptosis 
Cleaved PARP 
Significant reductions in cleaved PARP levels were observed in AECs in the NRTI/NNRTI treatment 
group (0.74 ± 0.05 vs. 1 ± 0.03; p=0.03) and in the HIV + PI treatment group (0.64 ± 0.05 vs. 1 ± 0.03; 
p=0.002) compared to the combined vehicle control. An ordinary one-way ANOVA with Tukey‟s multiple 
comparisons tests was performed. 
 
 
 
Figure 3.20: Cleaved PARP after 24 hours. CVC: Combined vehicle control; HIV: HIV-protein cocktail; 
NRTI/NNRTI: nucleoside analogue reverse transcriptase inhibitors/non-nucleoside reverse transcriptase 
inhibitors; PI: protease inhibitors. *: p<0.05; **: p<0.01. Arbitrary units: pixel counts depicted here as ratios 
relative to the CVC, which was expressed as 1. n=3/group. 
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Cleaved Caspase-3 
None of the interventions had any effects on cleaved caspase-3 levels. An ordinary one-way ANOVA with 
Tukey‟s multiple comparisons test was performed. 
 
 
Figure 3.21: Cleaved Caspase-3 after 24 hours. CVC: Combined vehicle control; HIV: HIV-protein 
cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase inhibitors/non-nucleoside reverse 
transcriptase inhibitors; PI: protease inhibitors. Arbitrary units: pixel counts depicted here as ratios relative 
to the CVC, which was expressed as 1. n=3/group, except HIV + PI, where n=2. 
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3.4.4 Nitrosative Stress 
Nitrotyrosine 
None of the interventions had any effects on nitrotyrosine levels. An ordinary one-way ANOVA with 
Tukey‟s multiple comparisons test was performed. 
  
 
 
Figure 3.22: Nitrotyrosine levels after 24 hours. CVC: Combined vehicle control; HIV: HIV-protein 
cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase inhibitors/non-nucleoside reverse 
transcriptase inhibitors; PI: protease inhibitors. Arbitrary units: pixel counts depicted here as ratios relative 
to the CVC, which was expressed as 1. n=3/group, except HIV + NRTI/NNRTI and HIV + PI, where n=2. 
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3.4.5 Oxidative Stress 
p22phox 
None of the interventions had any effects on p22phox levels. An ordinary one-way ANOVA with Tukey‟s 
multiple comparisons test was performed. 
 
 
Figure 3.23: p22phox levels after 24 hours. CVC: Combined vehicle control; HIV: HIV-protein cocktail; 
NRTI/NNRTI: nucleoside analogue reverse transcriptase inhibitors/non-nucleoside reverse transcriptase 
inhibitors; PI: protease inhibitors. Arbitrary units: pixel counts depicted here as ratios relative to the CVC, 
which was expressed as 1. n=3/group. 
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CHAPTER 4: DISCUSSION AND CONCLUSION  
 
What follows is a general discussion of all the results of this study, commencing with the time- and 
concentration-response investigations and thereafter, the vascular signalling protein analyses. This is 
succeeded by a summary of the primary findings, integrating the results from the various experimental 
procedures and finally leading up to the conclusion. It is worth mentioning that literature searches yielded 
no evidence of previous studies investigating the combined effects of HIV-1-proteins and antiretroviral 
drugs on endothelial cells in an in vitro setting, which, whilst adding novelty to the results, makes 
contextualisation difficult. 
 
4.1 GENERAL DISCUSSION 
4.1.1 Time- and Concentration-Response Investigations 
HIV-1-Protein Medium 
Table 4.1: Summary of HIV-1-protein medium time- and concentration-response investigation 
results 
 25 ng/ml 50 ng/ml 100 ng/ml 
24 hours of HIV-1-protein exposure 
Non-viable cells (Propidium Iodide probe) - - - 
NO production (DAF-2/DA probe) - - ↓ vs. Control 
Nitrosative stress (DHR-123 probe) - - - 
48 hours of HIV-1-protein exposure 
Non-viable cells (Propidium Iodide probe) - - ↑ vs. 25 ng/ml 
NO production (DAF-2/DA probe) - - - 
Nitrosative stress (DHR-123 probe) - - - 
25 ng/ml, 50 ng/ml or 100 ng/ml of Tat, Gp160 and Nef were added to endothelial growth medium and the effects on 
cell viability, NO production and nitrosative stress assessed. 
 
Exposure to 100 ng/ml of HIV-1 Nef, Tat and Gp160 (Gp120 + Gp41) for 24 hours led to a significant 
decrease in NO production in AECs (Figure 3.2), with no effect on nitrosative stress or cell viability. NO 
levels seemed to normalise with 48 hours of HIV-1 protein exposure, with no significant differences 
between treatment and control groups. A slight increase in non-viable cells was observed for 48 hours of 
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100 ng/ml of HIV-1 protein treatment, however only compared to the 25 ng/ml group and not the control 
(Figure 3.4). The reduction in NO observed after 24 hours of HIV-1 protein exposure is corroborated by 
other studies of a similar nature. Human coronary artery endothelial cells pre-treated with TNF-α and then 
exposed to 1 μg/ml of Gp120 for 16 hours showed a significant reduction in NO levels (Jiang et al., 2010). 
Similarly, in human pulmonary artery endothelial cells treated with 10 ng/ml or 50 ng/ml of Nef, NO 
production was reduced in a concentration-dependent manner (Duffy et al., 2009). However, neither of 
the aforementioned studies investigated NO production in endothelial cells exposed to more than 24 
hours of HIV-1 proteins, making it difficult to contextualise the 48-hour results. A possible explanation for 
the normalisation of the NO levels observed in this experimental group is that the initial reduction was 
transient in nature with cellular adaptive mechanisms coming into play over time; however, more research 
is needed to substantiate this observation. Most reviewers have attributed reductions in endothelial NO 
bioavailability to increased oxidative stress (Higashi et al., 2009; Förstermann and Sessa, 2012; Maron 
and Michel, 2012; Mudau et al., 2012), via the inactivation of NO by its reaction with superoxide (O₂¯), a 
potent ROS, turning it into peroxynitrite, as well as the uncoupling of eNOS, rendering the enzyme 
dysfunctional (Förstermann and Sessa, 2012; Mudau et al., 2012). Contrary to expectation, no changes 
were observed in the levels of nitrosative stress as assessed by DHR-123, which detects increases in 
peroxynitrite and thus potential increases in O₂¯ and by extension oxidative stress. In contrast, most other 
researchers have noted increases in ROS and oxidative stress associated with HIV-1-proteins. Duffy et 
al. (2009) found that the decreased NO they observed was linked to increased superoxide (O₂¯). In other 
studies HIV-1-proteins were also linked to oxidative stress. In rat brain endothelial cells, exposure to 1 μg 
of Tat and 1 μg or 2 μg of Gp120 for 2 hours resulted in an increase in oxidative stress (Price et al., 2005) 
and in human pulmonary artery endothelial cells exposure to different concentrations of Tat (100, 250 and 
500 ng/ml) for 1 hour all resulted in significant increases in ROS (Liu et al., 2005). However, for this thesis 
O₂¯ and other ROS production were not assessed directly. Only nitrosative stress was considered, 
specifically peroxynitrite detection by DHR-123, and since this product is not produced by cells directly, 
but via the reaction of NO with O₂¯, one could speculate that cellular antioxidant defences, such as 
superoxide dismutase, could possibly have counteracted slight increases in O₂¯, causing its detection to 
be missed. A further possibility with regards to the discrepancy is the differences in the concentrations of 
HIV-1 proteins utilised. Most researchers exposed cells to a higher concentration of HIV-1 proteins 
compared to what was used for the present study (Liu et al., 2005; Price et al., 2005; Jiang et al., 2010). 
Other researchers have reported increases in markers of apoptosis upon the exposure of endothelial cells 
to HIV-1 proteins for 12 or 24 hours (Park et al., 2001; Wang et al., 2014). For this thesis only a slight 
increase in non-viable cells was noted after 48 hours of HIV-1 protein exposure. However, Park et al. 
(2001) and Wang et al. (2014) looked at specific markers of apoptosis only, including DNA fragmentation, 
while the propidium iodide probe used here detects loss of cell membrane integrity as found in necrosis, 
which could explain why decreases in cell viability were only noted at 48 hours, when the HIV-1 proteins 
could have caused more severe cell damage. 
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Antiretroviral Drug Treatment 
 
Table 4.2 Summary of ART treatment concentration-response investigation results 
 Half Dose (HD) Single Dose (SD) Double Dose (DD) 
NRTI/NNRTI treatment in HIV-1-protein medium 
Non-viable cells (Propidium Iodide probe) - - ↑ vs. HD & SD 
NO production (DAF-2/DA probe) - - - 
Nitrosative stress (DHR-123 probe) ↓ vs. Control ↓ vs. Control ↓ vs. Control 
PI treatment in HIV-1-protein medium 
Non-viable cells (Propidium Iodide probe) - - ↑ vs. HD & SD 
NO production (DAF-2/DA probe) - ↓ vs. Control & HD ↓ vs. Control, HD & SD 
Nitrosative stress (DHR-123 probe) - - - 
Different dosages of NRTI/NNRTI (efavirenz, tenofovir and emtricitabine) or PI (lopinavir and ritonavir) antiretroviral 
drugs were added to HIV-1-protein medium (containing 100 ng/ml each of Tat, Gp160 and Nef) and the effects on cell 
viability, NO production and nitrosative stress assessed. HD: half dose; SD: single dose; DD: double dose. 
 
NRTI/NNRTI treatment within an HIV-1-protein medium environment for 24 hours had no effect on NO 
production, possibly abrogating the reduced levels observed with HIV-1-protein treatment on its own, 
although clear conclusions cannot be drawn from these experiments as an HIV-1-protein group was not 
included due to technical constraints, making this merely a speculation. Furthermore, combined 
NRTI/NNRTI and HIV-1-protein treatment led to a reduction in nitrosative stress (Figure 3.9) and had 
minimal effects on cell viability, with only the highest concentration of NRTI/NNRTI treatment showing a 
slight increase in non-viable cells and this was not compared to the control (Figure 3.7). Of the three 
drugs in the NRTI/NNRTI cocktail, efavirenz has mostly been implicated in having detrimental endothelial 
consequences. In a transformed human umbilical vein endothelial cell line, 24 hours of efavirenz 
treatment negatively impacted cell viability in a concentration dependent manner. It also resulted in a 
concentration-dependent increase in apoptosis and necrosis. In contrast, tenofovir and emtricitabine had 
no effects (Faltz et al., 2017). In another study utilising the same cell line, efavirenz induced a gradual 
decrease in cell viability over 72 hours of treatment (Weiß et al., 2016). Efavirenz has also been linked to 
increased ROS production and oxidative stress in endothelial cells by a number of researchers 
(Jamaluddin et al., 2010; Weiß et al., 2016; Faltz et al., 2017). In contrast, tenofovir did not increase 
apoptotic or oxidative stress gene expression in human coronary artery endothelial cells (Kim et al., 
2011). Some of the abovementioned results are contradictory to what was found by the present thesis. A 
possible explanation for this discrepancy is that while most researchers investigated these drugs in 
isolation, an NRTI/NNRTI cocktail was utilised in this case, making it conceivable that tenofovir and 
emtricitabine, drugs that have not been linked to negative endothelial consequences, counteracted the 
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detrimental effects of efavirenz. Furthermore, protocol differences with regards to exposure time and 
concentrations could also have had an impact. It is additionally worth reiterating that the investigations 
were conducted within an HIV-1 protein environment, which was not the case in most of the available 
literature.  
PI treatment within an HIV-1-protein medium environment for 24 hours resulted in a reduction in NO 
production in a concentration-dependent manner (Figure 3.11). Furthermore, the HIV-1 + PI combination 
treatment had no effect on nitrosative stress and had minimal consequences for cell viability, with only the 
highest concentration of PI treatment showing a slight increase in non-viable cells, and not compared to 
the control (Figure 3.10). In human coronary artery endothelial cells exposed to 20 days of clinically 
relevant concentrations of lopinavir boosted with ritonavir, Auclair et al. (2014) showed that NO levels 
were significantly reduced and that this reduction was linked to oxidative stress. In human pulmonary 
artery endothelial cells, 24 hours of ritonavir treatment caused a significant increase in O₂¯ production 
(Wang et al., 2009). In the present study, an increase in nitrosative stress was not noted via DHR-123, 
and as described before, by extension O₂¯ production and oxidative stress. However, Wang et al. (2009) 
assessed O₂¯ production directly, whereas here it was measured indirectly via peroxynitrite formation and 
thus, as mentioned before, it is possible that cellular antioxidant defences could have mitigated these 
effects. Auclair et al., (2014) also assessed oxidative stress more indirectly, but using different markers. 
Interestingly, none of the papers found investigating the endothelial consequences of lopinavir and/or 
ritonavir treatment reported on their effects on cell viability.  
4.1.2. Vascular signalling proteins 
Table 4.3: Summary of vascular signalling protein investigation results  
 HIV-
protein 
medium 
NRTI/ 
NNRTI 
treatment 
PI 
treatment 
NRTI/NNRTI 
treatment in HIV-
protein medium 
PI treatment in 
HIV-protein 
medium 
Total eNOS 
- - - - 
↓ vs. Control, PI & 
HIV 
Phospho eNOS - - - - - 
Total PKB/Akt ↓ vs. Control ↓ vs. Control ↓ vs. Control ↓ vs. Control ↓ vs. Control & HIV 
Phospho PKB/Akt - - - - - 
IκBα 
- - - - 
↓ vs. Control, HIV & 
HIV + NRTI/NNRTI 
Nitrotyrosine - - - - - 
p22phox - - - - - 
Cleaved caspase-3 - - - - - 
Cleaved-PARP - ↓ vs. Control - - ↓ vs. Control 
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eNOS and PKB/Akt  
Total eNOS expression was significantly reduced in AECs only when exposed to combined HIV-1-protein 
and PI treatment for 24 hours, with no effects on the phosphorylation of this protein (Figure 3.17). 
Interestingly the expression of PKB/Akt, an upstream activator of eNOS, was reduced in all groups, but 
especially in the combined HIV-1-protein and PI treatment group. No effects were observed on PKB/Akt 
phosphorylation (Figure 3.18). It would appear that no other studies have assessed the effects of 
NRTI/NNRTIs or PIs on endothelial cells within an HIV-1-protein microenvironment. However, in isolation, 
both HIV-1-proteins and PI drugs have been shown to reduce eNOS expression (Duffy et al., 2009; Wang 
et al., 2009; Jiang et al., 2010; Auclair et al., 2014). With regards to NRTI/NNRTI treatment, the results of 
this thesis do correspond with Weiß et al. (2016), where pharmacologically relevant concentrations of 
efavirenz were shown to have no effect on eNOS expression. Most of the literature focussed on eNOS 
expression while not reporting on its phosphorylation or on the expression/phosphorylation of PKB/Akt, 
making it difficult to contextualise findings. When speculating with regards to possible explanations for the 
observed decreases in PKB/Akt expression with unaffected eNOS phosphorylation for the HIV-1-protein, 
NRTI/NNRTI, PI and combined HIV-1-protein and NRTI/NNRTI treatment groups, it is worth noting that 
PKB/Akt is only one of several kinases responsible for the activation of eNOS by its phosphorylation at 
serine 1177 (Förstermann and Sessa, 2012) and thus reductions in PKB/Akt expression would not 
necessarily lead observable decreases in eNOS phosphorylation. Another possible explanation as to why 
changes in the phosphorylation of PKB/Akt and eNOS was not noted, is that phosphorylation usually 
constitutes an immediate form of protein activation, while changes in the transcription levels of a protein 
generally take longer. Here, the phosphorylation status of these proteins was only assessed at one time-
period (after 24 hours of HIV-1-protien and/ or antiretroviral drug exposure) and thus more immediate 
changes could have been missed. 
IκBα  
PI treatment within an HIV-1-protein environment led to a significant reduction in IκBα levels (Figure 
3.19). IκBα forms part of the canonical NFκB activation pathway where it acts as an inhibitor of NFκB. The 
proteolysis of IκBα results in the nuclear translocation of NFκB from the cytosol leading to the 
transcription of various inflammatory genes (Brasier, 2010). A reduction in cellular IκBα levels would thus 
be indicative of inflammation. Augmented NFκB signalling in response to HIV-1 proteins as well as PI 
treatment has been reported in a number of in vitro endothelial studies (Liu et al., 2005; Duan et al., 2013; 
Auclair et al., 2014; Wang et al., 2014). In human coronary artery endothelial cells, lopinavir boosted with 
ritonavir (LPV/r) markedly increased RelA/p65 (a subunit of NFκB) phosphorylation (Auclair et al., 2014). 
However, this was on the serine 536 residue, which is thought to act independently of the IκBα canonical 
pathway (Sasaki et al., 2005; Brasier, 2010). Furthermore, it was observed without HIV-1-protein co-
treatment, whereas, in the present study, a significant reduction in IκBα was only noted with combined 
HIV-1-protein and PI treatment. Furthermore, cells were exposed to LPV/r treatment for a much longer 
period (20 days) compared to the protocol followed here, possibly accounting for this difference. HIV-1 
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Tat protein treatment of human umbilical vein endothelial cells was shown to induce the nuclear 
translocation of NFκB-RelA/p65 in a time-dependent manner (Duan et al., 2013), similarly, in human 
pulmonary artery endothelial cells, Tat treatment increased NFκB transcriptional activity, and this also 
appeared to be time-dependent (Liu et al., 2005). However, in the study by Liu et al. a much higher 
concentration of recombinant Tat was used (250 ng/ml) compared to this protocol, possibly accounting for 
the reason no IκBα effects were detected for the HIV-1-protein treatment in isolation. HIV-1 Nef has been 
shown to induce the production of the inflammatory mediator, monocyte chemoattractant protein-1 (MCP-
1), in an NFκB dependent manner (Wang et al., 2014).  
Nitrotyrosine and p22phox  
Contrary to expectation no changes in the levels of nitrotyrosine (indicative of peroxynitrite and nitrosative 
stress) or p22phox (indicative of oxidative stress) were observed. Other researchers however, have 
reported increases in oxidative stress and ROS in endothelial cells exposed to HIV-1-proteins (Liu et al., 
2005; Price et al., 2005) as well as efavirenz (Jamaluddin et al., 2010; Weiß et al., 2016; Faltz et al., 
2017) and lopinavir and/or ritonavir (Wang et al., 2009; Auclair et al., 2014). In the present study O₂¯ and 
other ROS production were not assessed directly and only one protein marker of oxidative stress, namely 
p22phox, was measured, creating the possibility that oxidative stress could have been overlooked. 
Furthermore, none of the abovementioned studies assessed levels of p22phox, making true comparisons 
impossible. Observations with regards to nitrotyrosine levels correspond with the fluorescence-based 
assay results, where no increases in nitrosative stress were observed, as assessed by DHR-123 – a 
probe which detects peroxynitrite, the molecule primarily responsible for the nitration of the amino acid 
tyrosine and the consequent formation of nitrotyrosine (Duncan, 2003). However, no endothelial cell 
research within the framework of HIV and ART effects on markers of nitrosative stress was found, making 
it difficult to contextualise findings. 
Cleaved caspase-3 and cleaved-PARP  
No changes in the levels of cleaved caspase-3 were noted, while significant decreases in the levels of 
cleaved-PARP were observed for the NRTI/NNRTI treatment group as well as the combined HIV-1-
protein and PI treatment group (Figure 3.20). These results did not corroborate those reported in the 
literature. Faltz et al. (2017) showed that efavirenz time- and concentration- dependently increased PARP 
activity, while tenofovir and emtricitabine did not. In a study by Weiß et al. (2016), efavirenz induced slight 
PARP cleavage, but only at high drug concentrations. A possible reason for the discrepancy between the 
results of the present study and those reported in the literature, is that the levels of cleaved PARP were 
assessed only at one time period (24 hours) and for a single dosage of NTRI/NNRTI drugs. It is also 
possible, as mentioned before, that the tenofovir and emtricitabine components of the NRTI/NNRTI 
cocktail used mitigated the effects of efavirenz. While no changes in the levels of cleaved-PARP and 
cleaved caspase-3 were observed in AECs exposed to HIV-1-proteins here, some researchers did.  Park 
et al. (2001) report that the induction of apoptosis by PARP-cleavage followed Tat exposure for 24 hours 
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and this was mediated by caspase-3. Unfortunately, literature searches yielded no endothelial cell studies 
investigating these biomarkers of apoptosis subsequent to lopinavir and/or ritonavir treatment within the 
context of HIV-1-proteins, making it difficult to interpret the results in this regard.  
 
4.2 PRIMARY FINDINGS 
HIV-1 Nef, Tat and Gp160 attenuate eNOS-independent NO production in AECs  
Exposure to 100 ng/ml of HIV-1 Nef, Tat and Gp160 for 24 hours led to a significant decrease in NO 
production in AECs. Yet, this was not accompanied by changes in nitrosative stress or peroxynitrite 
measurements, or oxidative stress markers, and not associated with reduced eNOS expression or 
phosphorylation. Decreased NO levels in endothelial cells subsequent to HIV-1-protein exposure has 
been reported by a number of investigations, however, this finding has generally been associated with 
reduced eNOS expression and increased oxidative stress (Liu et al., 2005; Price et al., 2005; Duffy et al., 
2009; Jiang et al., 2010), warranting further investigations into the cause behind this discrepancy with the 
results of the present study.   
Efavirenz, Tenofovir and Emtricitabine treatment of HIV-1 Nef, Tat and Gp160 exposed AECs have 
minimal adverse effects, and could possibly even be beneficial. 
NRTI/NNRTI treatment within an HIV-1-protein medium environment for 24 hours had no effect on NO 
production, possibly abrogating the reduced levels observed with HIV-1-protein treatment on its own. 
However, this is merely speculation due to the absence of an HIV-1-protein group for these experiments. 
eNOS expression was also unaffected. Furthermore, reductions in nitrosative stress was noted and no 
indications of apoptosis. While efavirenz on its own has been linked to detrimental endothelial cell 
consequences, mostly in terms of increased ROS/oxidative stress and apoptosis, tenofovir and 
emtricitabine have not (Jamaluddin et al., 2010; Kim et al., 2011; Weiß et al., 2016; Faltz et al., 2017), 
creating the possibility that in cocktail form, the adverse effects of efavirenz are counteracted, perhaps 
explaining why this decrease in nitrosative stress levels was observed and no evidence of apoptosis 
induction found. Furthermore, combined efavirenz, tenofovir and emtricitabine treatment could possibly 
be beneficial to endothelial cells exposed to HIV-1-proteins, as the proteins‟ detrimental effects on NO 
production were potentially mitigated. However, since no studies have investigated the combined effects 
of efavirenz, tenofovir and emtricitabine treatment in an HIV-1-protein environment on endothelial cells, 
further investigation is needed to support this speculation.  
The interaction between Lopinavir/Ritonavir treatment and HIV-1 Nef, Tat and Gp160 result in a 
downregulation of the eNOS-NO biosynthesis pathway in AECs. 
PI treatment within an HIV-1-protein medium environment for 24 hours resulted in a reduction in NO 
production in a concentration-dependent manner, probably due to decreased total eNOS expression. 
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Interestingly, neither HIV-1 protein exposure on its own, nor PI treatment in isolation had any effects on 
eNOS, while, in combination, they seemed to interact, causing a significant reduction in the expression of 
this enzyme. In endothelial cells, decreased NO levels and eNOS expression have been associated with 
HIV-1-proteins on their own (Duffy et al., 2009; Jiang et al., 2010) as well as with lopinavir/ritonavir 
treatment in isolation (Wang et al., 2009; Auclair et al., 2014), however, no studies have investigated the 
endothelial effects of lopinavir/ritonavir treatment in an HIV-1-protein environment, making the findings of 
the present study novel in this regard. Nevertheless, more research is needed into the mechanisms 
involved, as increases in oxidative or nitrosative stress were not detected and this is generally accepted 
to be the pathophysiological process responsible for reduced NO and eNOS in endothelial cells (Higashi 
et al., 2009; Förstermann and Sessa, 2012; Maron and Michel, 2012; Mudau et al., 2012). 
The interaction between Lopinavir/Ritonavir treatment and HIV-1 Nef, Tat and Gp160 result in 
increased inflammatory NFκB signalling and possibly accounts for the downregulation of eNOS 
expression in AECs 
PI treatment within an HIV-1-protein environment led to a significant reduction in IκBα levels (indicative of 
increased NFκB signalling and inflammation), while neither HIV-1-protein treatment on its own nor PI 
treatment in isolation had any significant effects. Increased NFκB signalling in response to HIV-1 proteins 
as well as PI treatment has been reported in a number of endothelial cell studies (Liu et al., 2005; Duan et 
al., 2013; Auclair et al., 2014; Wang et al., 2014), yet, these investigations assessed at the effects of 
either individual HIV-1-proteins or PI drugs in isolation. Furthermore, Lee et al. (2014) implicated NFκB in 
the negative regulation of eNOS expression in human umbilical vein endothelial cells, via microRNA miR-
155. MicroRNAs are involved in regulating protein expression by targeting mRNAs for cleavage or 
translational repression (Bartel, 2004) and the possibility therefore arises that a similar mechanism was 
responsible for the reduced eNOS expression observed in the HIV-1 + PI group (Figure 4.1). However, 
more research is needed to substantiate this speculation. Additionally, no endothelial cell studies 
investigating NFκB signalling within a combined HIV-1-protein and PI treatment setting were found, 
highlighting the importance of the current work as well as emphasising the need for more research into 
this particular aspect of the HIV-ART-endothelial dysfunction interplay.  
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Figure 4.1: Proposed mechanism of eNOS-NO downregulation in response to combined HIV-1-
protein and PI drug treatment in endothelial cells. The interaction between the HIV-1-proteins Nef, Tat 
and Gp160 and PI drugs lopinavir and ritonavir result in decreased IκBα levels. IκBα is an inhibitor of 
NFκB and its downregulation results in the increased nuclear translocation of NFκB, augmenting pro-
inflammatory transcriptional activity. This has been linked to decreased eNOS expression, via post-
translational modifications mediated by microRNAs. PI: protease inhibitor; eNOS: endothelial nitric oxide 
synthase; NO: nitric oxide; NFκB: nuclear factor kappa-B; IκBα: nuclear factor kappa-B inhibitor alpha. 
 
4.3 CONCLUSION 
HIV-1 Nef, Tat and Gp160 attenuate NO production in endothelial cells, while efavirenz, tenofovir and 
emtricitabine treatment within this HIV-1 protein environment have minimal adverse effects. On the other 
hand, lopinavir and ritonavir treatment seemed to interact with these HIV-1 proteins resulting in a 
downregulation of the eNOS-NO biosynthesis pathway. This interaction was also observed for the 
inflammatory NFκB signalling pathway, which appeared to be upregulated, and possibly provides an 
explanation for the downregulation of eNOS expression detected. There is a paucity in the literature on 
the endothelial effects of combined HIV-1-protein and antiretroviral drugs, which given the evidence of 
interaction with regards to PIs, is problematic, especially since it is in this combined context that the 
endothelium of people living with HIV/AIDS and who are on PI-containing ART, may be affected. This 
emphasises the novelty of these findings, which may serve as a basis for future investigations into the 
HIV-1-PI interaction exposed by this thesis and additionally lead to an elucidation of the mechanisms 
involved and thus potentially aid in tailoring treatment for the growing population of people living with 
HIV/AIDS and who are also at increased cardiovascular risk. 
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CHAPTER 5: LIMITATIONS, RESEARCH OUTPUTS AND FUTURE 
DIRECTIONS 
 
5.1 LIMITATIONS 
 Time- and financial constraints meant that experiments could not be repeated to confirm or refute 
unexpected results, and prevented the inclusion of additional experimental groups investigating 
the individual drug components separately. 
 Technical constraints, due to the size of the 24-well plates used for the plate-reader analyses, 
meant that an HIV-1-protein group could not be included in the antiretroviral drug concentration 
response investigations, making it difficult to draw any clear conclusions from these results. 
 Low protein content of AECs furthermore meant that certain experimental groups could not be 
used for western blotting and thus reduced the final n-value of the vascular signalling protein 
analysis part of our study from five to three. 
 Only one time-point was chosen for the signalling protein western blot analyses; if time and 
finances allowed, more and earlier time-points could have been included to assess whether 
changes in the phosphorylation of signalling proteins (especially eNOS) were not missed.  
 
5.2 RESEARCH OUTPUTS ASSOCIATED WITH THIS STUDY 
Peer-reviewed publication 
 Review article: Marincowitz, C. et. al. (2018) „Vascular endothelial dysfunction in the wake of 
HIV and ART‟, The FEBS Journal. doi: 10.1111/febs.14657. (View in Appendix A). 
Peer-reviewed conference abstracts 
 National conference: Marincowitz, C., Strijdom, H., Charania, S. and Genis, A. „The effects of 
HIV-1 proteins and antiretroviral therapy on aortic endothelial cells (AECs) – a mechanistic in vitro 
approach‟. First Conference of Biomedical and Natural Sciences and Therapeutics (CoBNeST), 
Spier Estate, Stellenbosch, 7 – 10 October 2018. 
 International conference with published abstract: Genis, A., Ogundipe, T. P., Marincowitz, 
C., Strijdom, H. „Investigating endothelial dysfunction as a pathophysiological consequence of 
HIV-infection and anti-retroviral treatment‟.  2018/4/1.  Journal Cardiovascular Research, 114, 
suppl_1, pages S43. 
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Other conference proceedings 
 University Research Day: Marincowitz, C., Strijdom, H., Charania, S. and Genis, A. „The 
effects of HIV-1 proteins and antiretroviral therapy on aortic endothelial cells (AECs) – a 
mechanistic in vitro approach‟.  Department of Biomedical Sciences Annual Research Day, 
Stellenbosch University, Tygerberg Campus, 21 November 2018. (Received first prize for an oral 
presentation). 
 
5.3 FUTURE DIRECTIONS 
 To the best of our knowledge, this is the only study investigating the endothelial effects of 
common antiretroviral drugs within a simulated HIV-1-protein microenvironment. Thus, given the 
fact that we observed evidence of interaction between HIV-1-proteins and PI antiretroviral drugs 
(with regards to eNOS expression and inflammatory NFκB signalling), more research is needed 
to elucidate the mechanisms involved. 
 Given differences observed between our research and other similar studies, especially with 
regards to apoptosis and oxidative stress measures, we would recommend that more research, 
utilising different markers as well as incorporating additional concentrations and time-periods, be 
conducted to investigate these discrepancies. Also, the addition of individual drug component 
experiments will assist in understanding how the combined drug cocktail effects differ from the 
individual drugs in isolation. 
 While previous work in our laboratory indicated that one fully confluent 100 mm petri dish of 
cultured AECs yielded sufficient protein for one lysate, we found that this was not the case. Thus, 
for future similar investigations, we would recommend using two 100 mm petri dishes per lysate 
to ensure higher protein content and better blots.  
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APPENDIX B 
 
HIV-1-protein Medium and Vehicle Control Cocktail  Dilutions 
For HIV-Medium 1:  
Gp160 – 25ng/ml 
Calculation for dosage of Gp160: 
For a final concentration of 25ng/ml of Gp160 in 1ml of medium: 
We make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 1mg/ml  (this is the concentration at which we received the protein) 
C2 = 25ng/ml  (this is the final, working concentration that we want) 
V1 = X   (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml   (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
1000ug/ml x X = 0.025ug/ml x 1000ul 
X = 0.025*1000/1000 
X = 0.025ul 
You have to add 0.025ul to 1ml of medium to get the final concentration, but it is a very small amount, so 
we prepare a stock that is x1000 concentrated 
Original conc.: 
25ng/ml  = 0.025ug/ml 
X1000: 
25ug/ml 
The protein is received in 1mg/ml 
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0.025mg / 1mg x 1ml = 0.025ml = 25µl 
*Thus take 25µl of original stock received (1mg/ml) and add to 975ul of PBS to get 1ml of an x1000 
concentrated stock of 25µg/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
To get the final correct concentration of 25ng/ml: 
C1V1 = C2V2 
25ug/ml x X = 25ng/ml x 1ml 
Change all to micro-units: 
25  x X = 0.025  x 1000 
X    = 0.025*1000/25 
    = 1 
Thus, add 1ul of x1000 stock in 1ml of medium to get 25ng/ml. 
 
Nef – 25ng/ml  
Calculation for dosage of Nef: 
For a final concentration of 25ng/ml of Nef in 1ml of medium: 
We make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 1mg/ml  (this is the concentration at which we received the protein) 
C2 = 25ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
1000ug/ml x X = 0.025ug/ml x 1000ul 
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X = 0.025*1000/1000 
X = 0.025ul 
You have to add 0.025ul to 1ml of medium to get the final concentration, but it is a very small amount, so 
we prepare a stock that is x1000 concentrated 
Original conc.: 
25ng/ml = 0.025ug/ml 
X1000: 
25ug/ml 
The protein is received in 1mg/ml 
0.025mg / 1mg x 1ml = 0.025ml = 25µl 
*Thus take 25µl of original stock received (1mg/ml) and add to 975ul of PBS to get 1ml of an x1000 
concentrated stock of 25ug/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
To get the final correct concentration of 25ng/ml: 
C1V1 = C2V2 
25ug/ml x X = 25ng/ml x 1ml 
Change all to micro-units: 
25  x X = 0.025  x 1000 
X    = 0.025*1000/25 
    = 1 
Thus, add 1ul of x1000 stock in 1ml of medium to get 25ng/ml. 
 
Tat – 25ng/ml 
Calculation for dosage of Tat: 
For a final concentration of 25ng/ml of Tat in 1ml of medium: 
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We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 50ug/ml (this is the concentration that we will reconstitute the protein in) 
C2 = 25ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of a medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
50ug/ml x X = 0.025ug/ml x 1000ul 
X = 0.025*1000/50 
X = 0.5ul 
You have to add 0.5ul to 1ml of medium to get the final concentration.  
Thus, add 0.5ul of original stock in 1ml of medium to get 25ng/ml. 
 
HIV-Medium 1: 1μl Gp160, 1μ Nef and 0.5μl Tat stocks in 1ml growth medium 
Vehicle Control Cocktail  1: Thus 2.5μl of PBS in 1ml growth medium 
 
For HIV-Medium 2: 
Gp160 – 50ng/ml 
Calculation for dosage of Gp160: 
For a final concentration of 50ng/ml of Gp160 in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 1mg/ml  (this is the concentration at which we received the protein) 
C2 = 50ng/ml (this is the final, working concentration that we want) 
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V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
1000ug/ml x X = 0.050ug/ml x 1000ul 
X = 0.050*1000/1000 
X = 0.050ul 
You have to add 0.050ul to 1ml of medium to get the final concentration, but it is a very small amount, so 
we prepare a stock that is x1000 concentrated 
Original conc.: 
50ng/ml = 0.050ug/ml 
X1000: 
50ug/ml = 50ug/ml 
The protein is received in 1mg/ml 
0.050mg / 1mg x 1ml = 0.050ml = 50µl 
*Thus take 50µl of original stock received (1mg/ml) and add to 950ul of PBS to get 1ml of an x1000 
concentrated stock of 50µg/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
To get the final correct concentration of 50ng/ml: 
C1V1 = C2V2 
50ug/ml x X = 50ng/ml x 1ml 
Change all to micro-units: 
50  x X = 0.050  x 1000 
X    = 0.050*1000/50  = 1 
 
Thus, add 1ul of x1000 stock in 1ml of medium to get 50ng/ml. 
Stellenbosch University  https://scholar.sun.ac.za
123 
 
Nef – 50ng/ml  
Calculation for dosage of Nef: 
For a final concentration of 100ng/ml of Nef in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 1mg/ml  (this is the concentration at which we received the protein) 
C2 = 50ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
1000ug/ml x X = 0.050ug/ml x 1000ul 
X = 0.050*1000/1000 
X = 0.050ul 
You have to add 0.050ul to 1ml of medium to get the final concentration, but it is a very small amount, so 
we prepare a stock that is x1000 concentrated 
Original conc.: 
50ng/ml = 0.050ug/ml 
X1000: 
50ug/ml = 50ug/ml 
The protein is received in 1mg/ml 
0.050mg / 1mg x 1ml = 0.050ml = 50µl 
*Thus take 50µl of original stock received (1mg/ml) and add to 950ul of PBS to get 1ml of an x1000 
concentrated stock of 50µg/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
To get the final correct concentration of 50ng/ml: 
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C1V1 = C2V2 
50ug/ml x X = 50ng/ml x 1ml 
Change all to micro-units: 
50  x X = 0.050  x 1000 
X    = 0.050*1000/50  = 1 
Thus, add 1ul of x1000 stock in 1ml of medium to get 50ng/ml. 
  
Tat – 50ng/ml 
Calculation for dosage of Tat: 
For a final concentration of 50ng/ml of Tat in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 50ug/ml (this is the concentration that we will reconstitute the protein in) 
C2 = 50ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
50ug/ml x X = 0.050ug/ml x 1000ul 
X = 0.050*1000/50 
X = 1ul 
You have to add 1ul to 1ml of medium to get the final concentration, so we can leave at this. 
Thus, add 1ul of original stock in 1ml of medium to get 50ng/ml. 
 
HIV-Medium 2: 1μl Gp160, 1μl Nef and 1μl Tat stocks in 1ml growth medium 
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Vehicle Control Cocktail  2: Thus 3μl of PBS in 1ml of medium 
 
For HIV-Medium 3: 
Gp160 – 100ng/ml 
Calculation for dosage of Gp160: 
For a final concentration of 100ng/ml of Gp160 in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 1mg/ml  (this is the concentration at which we received the protein) 
C2 = 100ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
1000ug/ml x X = 0.100ug/ml x 1000ul 
X = 0.100*1000/1000 
X = 0.1ul 
You have to add 0.1ul to 1ml of medium to get the final concentration, but it is a very small amount, so we 
prepare a stock that is x1000 concentrated 
Original conc.: 
100ng/ml = 0.1ug/ml 
X1000: 
100ug/ml 
The protein is received in 1mg/ml 
100ug / 1000ug x 1000ul = 100µl 
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*Thus take 100µl of original stock received (1mg/ml) and add to 900ul of PBS to get 1ml of an x1000 
concentrated stock of 100µg/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
To get the final correct concentration of 50ng/ml: 
C1V1 = C2V2 
100ug/ml x X = 100ng/ml x 1ml 
Change all to micro-units: 
100  x X = 0.1  x 1000 
X    = 0.1*1000/100 
    = 1 
Thus, add 1ul of x100 stock in 1ml of medium to get 100ng/ml 
 
Nef – 100ng/ml *(Note: Nef was recalculated when new stock arrived – see later) 
Calculation for dosage of Nef: 
For a final concentration of 200ng/ml of Nef in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 1mg/ml  (this is the concentration at which we received the protein) 
C2 = 100ng/ml (this is the final, working concentration that we want) 
V1 =   (this is the volume of the protein in stock that we need to add to 1ml of 
medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
1000ug/ml x X = 0.100ug/ml x 1000ul 
X = 0.100*1000/1000 
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X = 0.1ul 
You have to add 0.1ul to 1ml of medium to get the final concentration, but it is a very small amount, so we 
prepare a stock that is x1000 concentrated 
Original conc.: 
100ng/ml = 0.1ug/ml 
X1000: 
100ug/ml 
The protein is received in 1mg/ml 
100ug / 1000ug x 1000ul = 100µl 
*Thus take 100µl of original stock received (1mg/ml) and add to 900ul of PBS to get 1ml of an x1000 
concentrated stock of 100µg/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
To get the final correct concentration of 50ng/ml: 
C1V1 = C2V2 
100ug/ml x X = 100ng/ml x 1ml 
Change all to micro-units: 
100  x X = 0.1  x 1000 
X    = 0.1*1000/100 
    = 1 
Thus, add 1ul of x100 stock in 1ml of medium to get 100ng/ml. 
 
Tat – 100ng/ml 
Calculation for dosage of Tat: 
For a final concentration of 100ng/ml of Ta in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
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Where: 
C1 = 50ug/ml (this is the concentration that we will reconstitute the protein in) 
C2 = 100ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
50ug/ml x X = 0.1ug/ml x 1000ul 
X = 0.1*1000/50 
X = 2ul 
Thus, add 2ul of stock in 1ml of medium to get 100ng/ml. 
  
HIV-Medium 3: 1ul of Gp160, 1ul of Nef and 2ul of Tat stocks in 1ml growth medium 
Vehicle Control Cocktail 3: 4ul of PBS in 1ml growth medium 
 
*New Nef – 100ng/ml 
Calculation for dosage of Nef: 
For a final concentration of 100ng/ml of Nef in 1ml of medium: 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 0.48mg/ml (this is the concentration at which we received the protein) 
C2 = 100ng/ml (this is the final, working concentration that we want) 
V1 = X  (this is the volume of the protein in stock that we need to add to 1ml of medium to get the final, working concentration)  
V2 = 1ml  (this is the amount of medium per plate in an experimental setup) 
Convert all to micro-units 
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480ug/ml x X = 0.1ug/ml x 1000ul 
X = 0.1*1000/480 
X = 0.208ul 
You have to add 0.208ul to 1ml of medium to get the final concentration, but it is a very small amount, so 
we prepare a stock that is x1000 concentrated 
Original conc.: 
100ng/ml = 0.1ug/ml 
X100: 
10ug/ml 
The protein is received in 20µg at concentration of 0.48mg/ml = 480µl/ml 
We Make use of the formula:  C1V1 = C2V2 
Where: 
C1 = 480µg/ml (this is the concentration at which we received the protein) 
C2 = 10µg/ml (this is the final concentration that we want) 
V1 = X  (this is the volume of the stock that we need to add to 500µl of PBS to get the x100 concentration)  
V2 = 500µl  (this is the amount of PBS we will add the stock to) 
 
480 x X = 10 x 500 
X   = 5000 / 480 
   = 10.416 
*Thus take 10µl of original stock received (0.48mg/ml) and add to 490ul of PBS to get 500µl of an x100 
concentrated stock of 10µg/ml. 
This step is to calculate how much of the concentrated stock we need to add to 1ml medium   
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To get the final correct concentration of 100ng/ml: 
C1V1 = C2V2 
10ug/ml x X = 100ng/ml x 1ml 
Change all to micro-units: 
100  x X = 0.1  x 1000 
X    = 0.1*1000/10 
    = 10 
Thus, add 10ul of x100 stock in 1ml of medium to get 100ng/ml. 
 
For New Nef Vehicle Control Cocktail: 10ul of PBS in 1ml of medium (instead of instead of 1ul) 
Thus Vehicle Control Cocktail 3: 13μl of PBS in 1ml medium. 
 
  
Stellenbosch University  https://scholar.sun.ac.za
131 
 
APPENDIX C 
 
Antiretroviral Drug Medium and Vehicle Control Cocktail  Dilutions 
NRTI/NNRTI Medium 
EFV: 5.6nM 
The 10 mg EFV powder received was dissolved in 1.5 ml of Methanol (MeOH) to create an EFV stock 
solution (21mM). This stock was then divided into 40 μl aliquots and frozen away at -20°C until needed.  
 
MW EFV  =  315.67 
For a concentration of 5.6nM EFV: 
MW EFV  =  315.67 
1M  = 315.67g/L 
1mM  = 315.67mg/L 
1µM  = 315.67µg/L 
1nM  = 0.31567µg/L 
5.6nM  = 1.767752µg/L 
  = 0.0017677µg/ml 
 
21mM x 40µl = 5.6µM x X 
21 x 0.040 = 0.0056 x X 
X  = 150ml 
 
Dissolve Methanol stock of 21mM (volume of 40µl) in 150ml PBS to get stock of 5.6µM. From this take 
1µl and add to 1ml growth medium to get final concentration.  
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FTC: 1.3µM 
The 10 mg FTC powder received was dissolved in 4 ml of dH₂O to create an FTC stock solution (10mM). 
This stock was then divided into 65 ul aliquots and frozen away at - 20 °C until needed.  
 
MW FTC  =  247.25 
For a concentration of 1.3µM FTC: 
MW FTC  =  247.25 
1M  = 247.25g/L 
1mM  = 247.25mg/L 
1µM  = 247.25µg/L 
1.3µM  = 321.425µg/L 
  = 0.321425µg/mL 
    
10mM x 65µl = 1.3mM x X 
10 x 0.065 = 1.3 x X 
X  = 0.5 ml 
 
Dissolve dH₂O stock of 10mM (volume of 65µl) in 0.5ml PBS to get stock of 1.3mM. From this take 1µl 
and add to 1ml growth medium to get final concentration. 
 
TDF: 500nM 
The 10 mg TDF powder received was dissolved in 40 ml of dH₂O to create a TDF stock solution (393µM). 
This was then divided into 350 μl aliquots and frozen away at -20 °C until needed.  
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MW TDF  =  635.51 
 
For a concentration of 500nM FTC: 
MW EFV  =  635.51 
1M  = 635.51g/L 
1mM  = 635.51mg/L 
1µM  = 635.51µg/L 
1nM  = 0.63551µg/L 
500nM  = 317.755µg/L 
  = 0.317755µg/ml 
 
393µM x 350µl = 0.5µM x X 
X  = 393 x 350 / 0.5 
X  = 275100µl 
  = 275ml 
 
Dissolve the dH₂O stock of 393µM (volume of 350µl) in 275ml PBS to get stock of 500µM. From this take 
1µl and add to 1ml medium to get final concentration. 
 
NRTI/NNRTI Vehicle Control Cocktail: 
To simplify calculations, we prepared a vehicle stock for each of the NRTI/NNRTI drugs: 
EFV vehicle stock: 40µl of methanol to 150ml of PBS  
TDF vehicle stock: 350µl of dH₂O to 275ml of PBS   
FTC vehicle stock: 65µl of dH₂O to 0.5ml of PBS  
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HIV Protein Vehicle: 8µl per 1ml of medium for all three proteins 
 
Prepare Vehicle control cocktail 1 (VC1): 
For 2ml: add 16µl of PBS + 1µl EFV vehicle stock + 1µl TDF vehicle stock + 1µl FTC vehicle stock to 
1.981ml medium 
Prepare Vehicle control cocktail 2 (VC2): 
For 2ml: add 16µl of PBS + 2µl EFV vehicle stock + 2µl TDF vehicle stock + 2µl FTC vehicle stock to 
1.978ml medium 
Prepare Vehicle control cocktail 3 (VC3): 
For 2ml: add 16µl of PBS + 4µl EFV vehicle stock + 4µl TDF vehicle stock + 4µl FTC vehicle stock to 
1.972ml medium 
 
PI Medium 
LPV: 10µM 
MW LPV  =  628.80 
For a concentration of 10µM LPV: 
MW LPV  =  628.80 
1M  = 628.80g/L 
1mM  = 628.80mg/L 
1µM  = 628.80µg/L 
  = 0.62880µg/mL 
10µM  = 6.2880µg/mL 
 
Prepare Stock x1000 times concentrated: 
10mM  = 6288.0µg/ml 
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The powder is received in 10mg that will be dissolved in 1ml DMSO [6.288mµg / 10mg x 1ml = 0.62880ml 
= 628.80µl in 1 ml]. Take 200µl of DMSO stock and add to 118µl DMSO to get x1000 concentrated stock 
of 10mM. From this, take 1µl in 1ml medium for final concentration of 10µM (x1000 diluted) 
 
RTV: 2µM 
MW RTV = 720.94 
For a concentration of 2µM RTV: 
MW RTV  =  720.94 
1M  = 720.94g/L 
1mM  = 720.94mg/L 
1µM  = 720.94µg/L 
  = 0.72094µg/mL 
2µM  = 1.4419µg/mL 
 
Prepare Stock x1000 times concentrated: 
2mM  = 1441.88µg/ml 
The powder is received in 10mg that will be dissolved in 1ml DMSO [1.44188mg / 10mg x 1ml = 
0.144188ml = 144.188µl in 1 ml]. Take 144µl of DMSO stock and add to 856µl DMSO to get x1000 
concentrated stock of 2mM. From this, take 1µl in 1ml medium for final concentration of 2µM (x1000 
diluted) 
PI Vehicle Control Cocktail: 
To simplify calculations, we prepare a vehicle stock for each of the PI drugs: 
LPV vehicle stock: Just DMSO 
RTV vehicle stock: Just DMSO 
HIV Protein Vehicle: 13µl PBS per 1ml of medium for all three proteins  
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Prepare Vehicle control cocktail 1 (VC1): 
For 2ml: add 26µl of PBS + 2µl DMSO to 1.972ml medium  
Prepare Vehicle control cocktail 2 (VC2): 
For 2ml: add 26µl of PBS + 4µl DMSO to 1.97ml medium 
Prepare Vehicle control cocktail 3 (VC3): 
For 2ml: add 26µl of PBS + 8µl DMSO to 1.966ml medium 
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APPENDIX D 
Passaging a P3 cell-line to 24-well plates. 
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Passaging a P2 cell-line to 24-well plates 
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 Passaging a P1 parent cell-line to 24-well plates 
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APPENDIX E 
 
Plate Reader Protocols 
Propidium Iodide (PI): 
1. In an Eppendorf tube, add 200ul of dH2O, and then turn off the fume-hood light. 
2. Vortex the PI and then transfer 100ul PI into the Eppendorf tube containing 200ul dH2O. [This will be 
enough to treat 29 wells] 
3. Thoroughly vortex the tube and cover from the light. 
4. Wash each well with 500ul warm PBS 
5. Add 990ul PBS to each well, excluding the wells to be used for positive controls – these wells get 
990ul dH2O instead. 
6. Re-vortex the PI mixture and add 10ul from the 300ul PI mixture to each well to have a total of 1ml 
per well. 
7. Place all plates in the incubator for 15 minutes. 
8. Leave the probe in & measure fluorescence using a plate-reader. 
 
DAF-2/DA: 
 
1. To prepare DAF, add 1ul of DAF from stock (Freezer draw) to 499ul of PBS per well (+ 1 extra). For 
24 plates (+1) = 25, you will have: 
 25 x 1ul DAF = 25ul of DAF 
 25 x 499ul PBS = 12.475ml of PBS 
2. Vortex this solution well. 
3. Wash plates once with 500ul PBS and add 500ul of the above DAF solution per well, for 2 hours. 
4. After 1h00, begin to prepare the positive control, DEA. 
5. Weigh off 0.001g DEA, which is found in the -80C freezer, and place it in an Eppendorf tube. 
6. After 1h20, add 50ul of PBS to the DEA Eppendorf tube and vortex well. 
7. After 1h30, add 0.5ul of the DEA solution to each positive control well and put back in the incubator 
for the final 30 minutes of the total 2 hours. 
8. After 2 hours, remove the probe, re-suspend in 500ul PBS per well and measure fluorescence using 
the plate-reader.  
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DHR-123: 
1. To prepare DHR, add 2ul of DHR from stock (55ul aliquots can be found in the liquid nitrogen; note: 
vortex before use) to 998ul of PBS per well (+ 1 extra). For 24 wells (+1) = 25, you will have: 
 25 x 2ul DHR = 50ul of DHR 
 25 x 998ul PBS = 24.950ml of PBS 
2. Vortex this solution well. 
3. Wash plates once with 500ul PBS and add 1ml of the above DHR solution per well, for 3 hours. 
4. After 45 minutes, remove the peroxynitrite from the -80 freezer and allow to thaw. 
5. After 1h00, add 0.56ul of peroxynitrite to each positive control well and put back in the incubator for 
the final 2 hours of the total 3 hours. 
6. Leave the probe in & measure fluorescence using the plate-reader. 
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APPENDIX F 
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APPENDIX G 
 
Table 3.2: Cell viability after 24 hours of HIV-1-protein exposure.  
 VC 1 25 ng/ml VC 2 50 ng/ml VC 3 100 ng/ml 
Mean % 100 104.5 100 98.01 100 100.5 
SEM % 0.66 11.41 0.63 1.41 0.41 3.06 
Data expressed as percentage propidium iodide fluorescence of vehicle control (vehicle control 
adjusted to 100%). VC 1: vehicle control for 25 ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 
ng/ml HIV-protein cocktail; VC 3: vehicle control for 100 ng/ml HIV-protein cocktail. 
 
Table 3.3: NO production after 24 hours of HIV-1-protein exposure.  
 VC 1 25 ng/ml VC 2 50 ng/ml VC 3 100 ng/ml 
Mean % 100 100.8 100 86.72 100 72.05* 
SEM % 1 5.25 0.92 9.26 1.55 8.37 
Data expressed as percentage DAF-2/DA fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for 25 ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-
protein cocktail; VC 3: vehicle control for 100 ng/ml HIV-protein cocktail. *: p<0.05 vs. VC 3 and 25 
ng/ml. 
 
Table 3.4: Nitrosative stress after 24 hours of HIV-1-protein exposure.  
 VC 1 25 ng/ml VC 2 50 ng/ml VC 3 100 ng/ml 
Mean % 100 103.4 100 94.47 100 86.81 
SEM % 0.8 5.67 1.05 6.78 1.7 13.53 
Data expressed as percentage DHR-123 fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for 25 ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-
protein cocktail; VC 3: vehicle control for 100 ng/ml HIV-protein cocktail.  
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Table 3.5: Cell viability after 48 hours of HIV-1-protien exposure.  
 VC 1 25 ng/ml VC 2 50 ng/ml VC 3 100 ng/ml 
Mean % 100 98.37 100 108.8 100 118.2* 
SEM % 1.15 4.61 0.82 5.31 0.49 7.69 
Data expressed as percentage propidium iodide fluorescence of vehicle control (vehicle control 
adjusted to 100%). VC 1: vehicle control for 25 ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 
ng/ml HIV-protein cocktail; VC 3: vehicle control for 100 ng/ml HIV-protein cocktail. *: p<0.05 vs. 25 
ng/ml. 
 
Table 3.6: NO production after 48 hours of HIV-1-protein exposure.  
 VC 1 25 ng/ml VC 2 50 ng/ml VC 3 100 ng/ml 
Mean % 100 94.72 100 100.9 100 91.62 
SEM % 0.26 3.03 0.31 5.49 0.32 5.28 
Data expressed as percentage DAF-2/DA fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for 25 ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-
protein cocktail; VC 3: vehicle control for 100 ng/ml HIV-protein cocktail.  
 
Table 3.7: Nitrosative stress after 48 hours of HIV-1-protein exposure.  
 VC 1 25 ng/ml VC 2 50 ng/ml VC 3 100 ng/ml 
Mean % 100 92.59 100 104.2 100 104.2 
SEM % 0.72 4.02 1.39 3.74 1.43 4.84 
Data expressed as percentage DHR-123 fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for 25 ng/ml HIV-protein cocktail; VC 2: vehicle control for 50 ng/ml HIV-
protein cocktail; VC 3: vehicle control for 100 ng/ml HIV-protein cocktail.  
 
Table 3.8: Cell viability after 24 hours of NRTI/NNRTI treatment within an HIV-1 environment.  
 VC 1 Half Dose VC 2 Single Dose VC 3 Double Dose 
Mean % 100 95.56 100 96.17 100 104.7* 
SEM % 0.17 0.63 0.46 3.4 0.3 2.7 
Data expressed as percentage propidium iodide fluorescence of vehicle control (vehicle control 
adjusted to 100%). VC 1: vehicle control for half dose treatment; VC 2: vehicle control for single dose 
treatment; VC 3: vehicle control for double dose treatment. *: p<0.05 vs. Half Dose and Single Dose. 
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Table 3.9: NO levels after 24 hours of NRTI/NNRTI treatment within an HIV-1 environment.  
 VC 1 Half Dose VC 2 Single Dose VC 3 Double Dose 
Mean % 100 100.6 100 99.78 100 100.3 
SEM % 0.43 0.56 0.44 1.88 0.18 2.65 
Data expressed as percentage DAF-2/DA fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for half dose treatment; VC 2: vehicle control for single dose treatment; 
VC 3: vehicle control for double dose treatment.  
 
Table 3.10: Nitrosative stress after 24 hours of NRTI/NNRTI treatment within an HIV-1 environment.  
 VC 1 Half Dose VC 2 Single Dose VC 3 Double Dose 
Mean % 100 86.57* 100 83.19** 100 86.14** 
SEM % 0.28 3.52 0.22 3.5 0.48 3.29 
Data expressed as percentage DHR-123 fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for half dose treatment; VC 2: vehicle control for single dose treatment; 
VC 3: vehicle control for double dose treatment. *: p<0.05 vs. VC 1; **: p<0.01 for Single Dose vs. VC 2 
and for Double Dose vs. VC 3. 
 
Table 3.11: Cell viability after 24 hours of PI treatment within an HIV-1 environment.  
 VC 1 Half Dose VC 2 Single Dose VC 3 Double Dose 
Mean % 100 94.26 100 94.33 100 106.7* 
SEM % 0.41 0.89 0.37 0.79 0.28 6.14 
Data expressed as percentage propidium iodide fluorescence of vehicle control (vehicle control 
adjusted to 100%). VC 1: vehicle control for half dose treatment; VC 2: vehicle control for single dose 
treatment; VC 3: vehicle control for double dose treatment. *: p<0.05 vs. Half Dose and Single Dose. 
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Table 3.12 NO levels after 24 hours of PI treatment within an HIV-1 environment.  
 VC 1 Half Dose VC 2 Single Dose VC 3 Double Dose 
Mean % 100 100.2 100 92.74** 100 85** *** 
SEM % 0.09 1.85 0.67 1.40 0.56 1.81 
Data expressed as percentage DAF-2/DA fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for half dose treatment; VC 2: vehicle control for single dose treatment; 
VC 3: vehicle control for double dose treatment. **: p<0.01 for Single Dose vs. VC 2 and Half Dose and 
for Double Dose vs. Single Dose; ***: p<0.001 for Double Dose vs. VC 3 and Half Dose. 
 
Table 3.13: Nitrosative stress after 24 hours of PI treatment within an HIV-1 environment.  
 VC 1 Half Dose VC 2 Single Dose VC 3 Double Dose 
Mean % 100 98.66 100 93.37 100 77.12 
SEM % 0.37 10.98 0.27 9.6 0.22 7.15 
Data expressed as percentage DHR-123 fluorescence of vehicle control (vehicle control adjusted to 
100%). VC 1: vehicle control for half dose treatment; VC 2: vehicle control for single dose treatment; 
VC 3: vehicle control for double dose treatment.  
 
Table 3.14: Cell viability after 24 hours of CVC exposure.  
 Control CVC 
Mean 100 96.89 
SEM 5.54 1.81 
Data expressed as percentage propidium iodide fluorescence of 
vehicle control (vehicle control adjusted to 100%). For Control 
n=3 and for CVC n=6. CVC: Combined Vehicle Control 
. 
Table 3.15: NO levels after 24 hours of CVC exposure.  
 Control CVC 
Mean% 100 98.3 
SEM% 0.77 0.77 
Data expressed as percentage propidium iodide fluorescence of 
vehicle control (vehicle control adjusted to 100%). For Control 
n=3 and for CVC n=6. CVC: Combined Vehicle Control. 
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Table 3.16: eNOS expression after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 1.17 1 0.93 0.66 0.28* ** 
SEM 0.21 0.16 0.09 0.1 0.01 0.04 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors. *: p<0.05 vs. CVC and 
PI; **: p<0.01 vs. HIV. 
 
Table 3.17: Phosphorylated eNOS after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.89 0.86 0.91 0.86 0.41 
SEM 0.22 0.14 0.13 0.08 0.04 0.17 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
 
Table 3.18: Phosphorylated / total eNOS ratio after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.76 0.85 0.99 1.31 1.34 
SEM 0.04 0.05 0.06 0.07 0.05 0.49 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
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Table 3.19: PKB/Akt expression after 24 hours.  
 CVC HIV* NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.84 0.79** 0.79** 0.83* 0.68* *** 
SEM 0.03 0.03 0.04 0.01 0.05 0.02 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors. *: p<0.05 for HIV vs. 
CVC, HIV+NRTI/NNRTI vs. CVC and HIV+PI vs. HIV; **: p<0.01 for NRTI/NNRTI vs. CVC and PI vs. 
CVC; ***: p<0.001 for HIV+PI vs. CVC. 
 
Table 3.20: Phosphorylated PKB/Akt after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.85 0.91 0.79 0.9 0.62 
SEM 0.06 0.07 0.1 0.13 0.05 0.05 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
 
Table 3.21: Phosphorylated / total PKB/Akt ratio after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 1.01 1.14 1 1.09 0.91 
SEM 0.08 0.06 0.09 0.16 0.07 0.04 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
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Table 3.22: IκBα expression after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.93 0.86 0.69 0.79 0.37* ** *** 
SEM 0.15 0.019 0.03 0.08 0.05 0.03 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors. *: p<0.05 vs. 
HIV+NRTI/NNRTI; **: p<0.01 vs. HIV; ***: p<0.001 vs. CVC. 
 
Table 3.23: Cleaved PARP after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.81 0.74* 0.79 0.81 0.64** 
SEM 0.03 0.07 0.05 0.02 0.06 0.05 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors. *: p<0.05 vs. CVC; **: 
p<0.01 vs. CVC. 
 
Table 3.24: Cleaved Caspase-3 after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.82 0.76 0.58 0.9 0.63 
SEM 0.05 0.11 0.16 0.12 0.23 0.46 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
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Table 3.25: Nitrotyrosine levels after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 2.39 2.74 2.95 2.54 0.54 
SEM 0.18 0.34 0.97 0.34 1.21 0.06 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
 
Table 3.26 p22phox levels after 24 hours.  
 CVC HIV NRTI/NNRTI PI HIV+NRTI/NNRTI HIV+PI 
Mean 1 0.89 0.7 0.58 0.96 0.51 
SEM 0.05 0.1 0.08 0.23 0.1 0.11 
Converted values. Original normalised pixel-counts expressed in relation to the CVC. CVC: Combined 
Vehicle Control. HIV: HIV-protein cocktail; NRTI/NNRTI: nucleoside analogue reverse transcriptase 
inhibitors/non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors.  
 
Stellenbosch University  https://scholar.sun.ac.za
151 
 
APPENDIX H 
 
Fluorescent Probe Functionality 
- For the propidium iodide assay, dH₂O was used as the positive control 
- For the DAF/2-DA assay, DEA/NO was used as the positive control 
- For the DHR-123 assay, peroxynitrite was used as the positive control 
HIV-Protein Model Time- and Concentration-Response Investigations 
24-hours 
   
  
 
 
*Upon investigation, it was ascertained 
that it was the positive control, DEA/NO, 
that did not function. 
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48-hours 
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Stellenbosch University  https://scholar.sun.ac.za
154 
 
 
  
 
ART Concentration-Response Investigations 
NRTI/NNRTI Treatment 
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PI Treatment 
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Combined Vehicle Control Test 
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APPENDIX I 
Below are images of the membranes (of transferred proteins from the 26-well Criterion™ TGX Stain-
Free™ gels) that were used by the Lab™- 5 software (Bio-Rad, CA, USA) for the TPN of the western blot 
data.  
Nitric Oxide Synthesis 
Total eNOS 
 
Total PKB/Akt 
 
Phospho eNOS 
 
Phospho PKB/Akt 
 
Inflammation 
IκBα 
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Apoptosis 
Cleaved PARP 
 
Cleaved Caspase-3 
 
Nitrosative Stress 
Nitrotyrosine 
 
Oxidative stress 
p22phox 
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